0001213900-16-018505.txt : 20161114 0001213900-16-018505.hdr.sgml : 20161111 20161114170929 ACCESSION NUMBER: 0001213900-16-018505 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161114 DATE AS OF CHANGE: 20161114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immudyne, Inc. CENTRAL INDEX KEY: 0000948320 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 760238453 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-184487 FILM NUMBER: 161995850 BUSINESS ADDRESS: STREET 1: 50 SPRING MEADOW ROAD CITY: MT. KISCO STATE: NY ZIP: 10549 BUSINESS PHONE: (914) 244-1777 MAIL ADDRESS: STREET 1: 50 SPRING MEADOW ROAD CITY: MT. KISCO STATE: NY ZIP: 10549 FORMER COMPANY: FORMER CONFORMED NAME: IMMUDYNE INC DATE OF NAME CHANGE: 19950720 10-Q 1 f10q0916_immudyne.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 333-184487

IMMUDYNE, INC.

(Exact name of registrant as specified in its charter)

Delaware		76-0238453
(State or other jurisdiction of		(IRS Employer
incorporation or organization)		Identification No.)

50 Spring Meadow Rd.
Mount Kisco, NY		10549
(Address of principal executive offices)		(Zip Code)

(914) 244-1777

(Registrant’s telephone number, including area code)

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days.

YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer, “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
(do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ☐ NO ☒

34,760,375 shares of common stock outstanding as of November 14, 2016.

Immudyne, Inc.

Table of Contents

		Page
Note about Forward-Looking Statements		i

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	22
Item 4.	Controls and Procedures	22

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Mine Safety Disclosures	23
Item 5.	Other Information	23
Item 6.	Exhibits	23

Signatures		24

Exhibit Index		25

NOTE ABOUT FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) regarding our company that include, but are not limited to, projections of earnings, revenue or other financial items; statements of the plans, strategies and objectives of management for future operations; statements concerning proposed new products, services or developments; statements regarding future economic conditions or performance; statements of belief; and statements of assumptions underlying any of the foregoing. These forward-looking statements are based on our current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by us. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “potential,” “believes,” “seeks,” “hopes,” “estimates,” “should,” “may,” “will,” “with a view to” and variations of these words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Although we believe that our expectations expressed in these forward-looking statements are reasonable, our expectations may later be found to be incorrect. Our actual results could be materially different from our expectations. Important risks and factors that could cause our actual results to be materially different from our expectations are set forth in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Our Business” and other sections in this report. Other sections of this report include additional factors that could adversely impact our business and financial performance.

Unless otherwise indicated, information in this report concerning economic conditions and our industry is based on information from independent industry analysts and publications, as well as our estimates. Except where otherwise noted, our estimates are derived from publicly available information released by third party sources, as well as data from our internal research, and are based on such data and our knowledge of our industry, which we believe to be reasonable. Unless otherwise indicated, none of the independent industry publication market data cited in this report was prepared on our or our affiliates’ behalf.

The forward-looking statements made in this report are based only on events or information as of the date on which the statements are made in this report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this report and the documents we refer to in this report and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from what we expect.

Additional information on the various risks and uncertainties potentially affecting our operating results are discussed in this report and other documents we file with the Securities and Exchange Commission (the “SEC”). We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on these forward-looking statements.

As used in this report, “Immudyne,” “Company,” “we,” “our” and similar terms refer to Immudyne Inc., unless the context indicates otherwise.

Immudyne, Inc

Consolidated Balance Sheets

	September 30, 2016			December 31, 2015
	(unaudited)
ASSETS

Current Assets
Cash	$	473,921		$	232,984
Trade accounts receivable, net		474,924			154,436
Inventory, net		130,530			61,051
Total Current Assets	$	1,079,375		$	448,471

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities
Accounts payable and accrued expenses	$	408,194		$	167,481
Notes payable, net of discount		214,115			100,000
Total Current Liabilities		622,309			267,481

Immudyne, Inc. Stockholders’ equity
Common stock, $0.01 par value; 50,000,000 shares authorized, 34,697,875 and 32,010,375 shares issued, 34,678,512 and 32,010,375 outstanding as of September 30, 2016 and December 31, 2015, respectively		346,978			320,103
Additional paid-in capital		9,032,728			8,366,313
Accumulated (deficit)		(9,075,014	)		(8,586,338	)
		304,692			100,078
Treasury stock,19,363 shares, at cost		(4,720	)		-
Total Immudyne, Inc. Stockholders’ Equity		299,972			100,078

Non-controlling interest		157,094			80,912

Total Stockholders’ Equity		457,066			180,990

Total Liabilities and Stockholders’ Equity	$	1,079,375		$	448,471

The accompanying notes are an integral part of these consolidated financial statements

Immudyne, Inc

Consolidated Statements of Operations

(unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015

Net sales	$	1,384,429		$	279,883		$	4,252,704		$	845,513

Cost of sales		942,738			73,988			2,981,657			237,707

Gross Profit		441,691			205,895			1,271,047			607,806

Operating expenses
Compensation and related expenses		361,829			101,137			1,077,340			301,301
Professional fees		82,608			29,237			277,282			91,059
General and administrative expenses		204,958			57,580			382,857			206,841
Total operating expenses		649,395			187,954			1,737,479			599,201

Operating Income (Loss)		(207,704	)		17,941			(466,432	)		8,605

Interest (expense)		(9,992	)		(14,422	)		(15,805	)		(33,048	)

Net Income (Loss) Before Taxes		(217,696	)		3,519			(482,237	)		(24,443	)
Deferred income tax benefit		-			4,600			-			13,200

Net Income (Loss)		(217,696	)		8,119			(482,237	)		(11,243	)

Net income (loss) attributable to noncontrolling interests		8,955			-			6,439			-

Net Income (loss) attributable to Immudyne, Inc.	$	(226,651	)	$	8,119		$	(488,676	)	$	(11,243	)

Basic and diluted (loss) per share attributable to Immudyne, Inc.	$	(0.01	)	$	0.00		$	(0.02	)	$	0.00

Average number of common shares outstanding
Basic		34,427,087			30,650,000			31,917,873			30,663,306
Diluted		34,427,087			30,650,000			31,917,873			30,663,306

The accompanying notes are an integral part of these consolidated financial statements

Immudyne, Inc

Consolidated Statement of Stockholders’ Equity

For the nine months ended September 30, 2016

(unaudited)

	Immudyne, Inc.
					Additional
	Common Stock				Paid-in		Accumulated			Treasury			Sub			Noncontrolling
	Shares		Amount		Capital		(Deficit)			Stock			Total			interest			Total

Balance at December 31, 2015		32,010,375	$	320,103	$	8,366,313	$	(8,586,338	)	$	-		$	100,078		$	80,912		$	180,990

Amortization of stock options		-		-		133,324		-			-			133,324			-			133,324

Issuance of common stock for services		2,300,000		23,000		283,667		-			-			306,667			-			306,667

Sale of common stock and warrants		200,000		2,000		44,000		-			-			46,000						46,000

Issuance of common stock in relation to debt offering		187,500		1,875		40,000		-			-			41,875						41,875

Issuance of warrants for services		-		-		20,585		-			-			20,585						20,585

Reduction in noncontrolling interest		-		-		91,612		-			-			91,612			(91,612	)		-

Purchase of treasury stock		-		-		-		-			(4,720	)		(4,720	)					(4,720	)

Issuance of stock options		-		-		53,227		-			-			53,227			-			53,227

Investment in subsidiary by noncontrolling interest		-		-		-		-			-			-			161,355			161,355

Net (loss)		-		-		-		(488,676	)		-			(488,676	)		6,439			(482,237	)

Balance at September 30, 2016		34,697,875	$	346,978	$	9,032,728	$	(9,075,014	)	$	(4,720	)	$	299,972		$	157,094		$	457,066

The accompanying notes are an integral part of these consolidated financial statements

Immudyne, Inc

Consolidated Statements of Cash Flows

(unaudited)

	Nine Months Ended September 30,
	2016			2015

CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss)	$	(482,237	)	$	(11,243	)
Adjustments to reconcile net (loss) to net cash (used) by operating activities
Depreciation		-			43,748
Bad debt provision		(43,558	)		-
Amortization of debt discount		5,990			-
Deferred tax benefit		-			(13,200	)
Stock compensation expense		493,218			14,500
Issuance of warrants for services		20,585			-
Changes in Assets And Liabilities
Trade accounts receivable		(276,930	)		(116,754	)
Inventory		(69,479	)		1,579
Accounts payable and accrued expenses		240,713			1,059
Net cash (used) by operating activities		(111,698	)		(80,311	)

CASH FLOWS FROM FINANCING ACTIVITIES
Investment in subsidiary by noncontrolling interest		161,355			-
Increase in notes payable		150,000			205,000
Repayment of notes payable		-			(115,522	)
Sale of common stock and warrants		46,000			-
Purchase of treasury stock		(4,720	)		(10,800	)
Net cash provided by financing activities		352,635			78,678

Net increase (decrease) in cash		240,937			(1,633	)

Cash at beginning of the period		232,984			75,495

Cash at end of the period	$	473,921		$	73,862

Supplemental Disclosure of Cash Flow Information
Cash paid during the period for interest	$	8,563		$	24,547

Issuance of common stock for notes payable	$	-		$	10,200
Issuance of common stock in relation to debt offering	$	41,875		$	-
Issuance of common stock for services	$	581,093		$	-

The accompanying notes are an integral part of these consolidated financial statements

Immudyne, Inc.

Notes to Consolidated Financial Statements

September 30, 2016

(unaudited)

1.	Organization and Going Concern

Immudyne, Inc. (the “Company”) is a Delaware corporation established to develop, manufacture and sell natural immune support products containing the Company’s proprietary yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast that have been shown through testing and analysis to support the immune system. The Company’s products include once a day oral intake tablets and topical creams and gels for skin application. The Company concentrates its sales and marketing efforts on healthcare professionals, distributors for its all-natural raw material ingredient products and direct-to-consumer sales.

In 2015, the Company formed a joint venture domiciled in Puerto Rico, Innate Skincare, LLC d/b/a Innate Scientific, LLC (“Innate”). Under the terms of the joint venture agreement, the Company held a 33.3% equity interest, and a 51% controlling voting interest, in Innate. On January 20, 2016, Innate amended its limited liability company operating agreement and changed its legal name to Immudyne PR LLC (“Immudyne PR”). On April 1, 2016, Immudyne PR further amended its operating agreement and restated the Company’s ownership and voting interest in Immudyne PR increased to 78.16667% resulting in a charge to noncontrolling interest and additional paid-in-capital of $91,612. Immudyne PR was formed to launch a complete skin care regime formulated using strategic ingredients provided by the Company. Immudyne PR is also currently pursuing other opportunities.

The Company has funded operations in the past through the sales of its products, issuance of common stock and through loans and advances from officers and directors. The Company’s continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers and directors or the issuance of additional shares of common stock.

The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. At September 30, 2016, the Company has an accumulated deficit approximating $9.1 million and has incurred negative cash flows from operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Based on the Company's cash balance at September 30, 2016, and projected cash needs for 2017, management estimates that it may need to increase sales revenue and/or raise additional capital to cover operating and capital requirements for the 2017 year. Management may raise the additional needed funds through increased sales volume, issuing additional shares of common stock or other equity securities, or obtaining debt financing. Although management has been successful to date in raising necessary funding, there can be no assurance that sales revenue will substantially increase or that any required future financing can be successfully completed on a timely basis, or on terms acceptable to the Company.

Immudyne, Inc.

Notes to Consolidated Financial Statements

September 30, 2016

(unaudited)

2.	Summary of Significant Accounting Policies

Unaudited Financial Statements

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for financial information and with the instructions to Form 10-Q. They do not include all information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The unaudited financial statements should be read in conjunction with those financial statements included in the Company’s previously filed Form 10-K for the year ended December 31, 2015. In the opinion of management, all adjustments considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

Basis of Presentation and Use of Estimates

The consolidated financial statements include the accounts of the Company and its controlled subsidiary, Immudyne PR. The non- controlling interest in Immudyne PR represents the 21.833% equity interest held by other members of the joint venture. All intercompany transactions have been eliminated.

The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the valuation of inventory and stockholders’ equity based transactions. Actual results could differ from those estimates.

Inventory

At September 30, 2016 and December 31, 2015, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic products. Inventory is maintained in the Company’s leased Kentucky warehouse and third party warehouses in Pennsylvania and Louisiana.

Immudyne, Inc.

Notes to Consolidated Financial Statements

September 30, 2016

(unaudited)

2.	Summary of Significant Accounting Policies (continued)

Inventory (continued)

Inventory is valued at the lower of cost or market with cost determined on a first-in, first-out (“FIFO”) basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to market value, if lower. At September 30, 2016 and December 31, 2015, the Company recorded an inventory reserve in the amount of $20,000. Inventory consists of the following:

	September 30, 2016		December 31, 2015

Raw materials	$	49,083	$	25,761
Finished products		81,447		35,290
	$	130,530	$	61,051

Revenue Recognition

The Company’s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer, and for sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped, but in limited cases if title does not pass until the product reaches the customer’s delivery site, then recognition of revenue is deferred until that time. Delivery is considered to have occurred when title and risk of loss have transferred to the customer. Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates approximated $530,000 and $1,578,000 in the three-month and nine-month periods ended September 30, 2016, respectively. Customer discounts, returns and rebates were not significant in the three-month and nine-month periods ended September 30, 2015.

Delivery is considered to have occurred when title and risk of loss have transferred to the customer. If title does not pass until the product reaches the customer’s delivery site or the customer accepts the product, then recognition of revenue is deferred until that time. There are no formal sales incentives offered to any of the Company’s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis.

Revenue for the nine-month period ended September 30, 2016 consisted of nutraceutical and cosmetic additives ($757,961) and finished cosmetic products ($3,494,743). Revenue for the nine month period ended September 30, 2015 consisted solely of nutraceutical and cosmetic additives. Revenue for the three-month period ended September 30, 2016 consisted of nutraceutical and cosmetic additives ($229,741) and finished cosmetic products ($1,154,688). Revenue for the three month period ended September 30, 2015 consisted solely of nutraceutical and cosmetic additives.

Accounts receivable

Accounts receivable are carried at original invoice amount less an estimate made for holdbacks and doubtful receivables based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers’ accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. At September 30, 2016 and December 31, 2015 the accounts receivable reserve was approximately $122,000 and $18,000, respectively.

Immudyne, Inc.

Notes to Consolidated Financial Statements

September 30, 2016

(unaudited)

2.	Summary of Significant Accounting Policies (continued)

Segments

The guidance for disclosures about segments of an enterprise requires that a public business enterprise report financial and descriptive information about its operating segments. Generally, financial information is required to be reported on the basis used internally for evaluating segment performance and resource allocation. The Company manages its operations in two reportable segments for purposes of assessing performance and making operating decisions. Revenue is generated predominately in the United States, and all significant assets are held in the United States, or United States territories.

A summary of the company’s reportable segments is as follows:

Total assets:

	September 30, 2016			December 31, 2015
Nutraceutical and Cosmetic Additives	$	519,646		$	412,324
Finished Cosmetic Products		695,205			101,828
Eliminations		(135,476	)		(65,681	)
Total	$	1,079,375		$	448,471

Total sales:

	Three months ended				Nine months ended
	September 30, 2016		September 30, 2015		September 30, 2016			September 30, 2015
Nutraceutical and Cosmetic Additives	$	229,741	$	279,883	$	780,961		$	845,513
Finished Cosmetic Products		1,154,688		-		3,494,743			-
Eliminations		-		-		(23,000	)		-
Total	$	1,384,429	$	279,883	$	4,252,704		$	845,513

Net (loss) income:

	Three months ended					Nine months ended
	September 30, 2016			September 30, 2015		September 30, 2016			September 30, 2015
Nutraceutical and Cosmetic Additives	$	(258,713	)	$	8,119	$	(653,757	)	$	(11,243	)
Finished Cosmetic Products		41,017			-		171,520			-
Eliminations		-			-		-			-
Total	$	(217,696	)	$	8,119	$	(482,237	)	$	(11,243	)

As of and for the nine months ended September 30, 2015, there were no assets, sales or net loss relative to the finished cosmetic products segment.

Immudyne, Inc.

Notes to Consolidated Financial Statements

September 30, 2016

(unaudited)

2.	Summary of Significant Accounting Policies (continued)

Income Taxes

The Company files Corporate Federal and State tax returns, while Immudyne PR, which was formed as a limited liability corporation, files a separate tax return with any tax liabilities or benefits passing through to its members.

The Company records current and deferred taxes in accordance with Accounting Standards Codification (ASC) 740, “Accounting for Income Taxes.” This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.

The Company’s tax returns for all years since December 31, 2012, remain open to taxing authorities.

Stock-Based Compensation

The Company follows the provisions of ASC 718, “Share-Based Payment”. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company’s shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.

Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.

Immudyne, Inc.

Notes to Consolidated Financial Statements

September 30, 2016

(unaudited)

2.	Summary of Significant Accounting Policies (continued)

Earnings (Loss) Per Share

Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive.

Common stock equivalents comprising shares underlying 12,950,273 options and warrants for the three and nine months ended September 30, 2016 have not been included in the loss per share calculation as the effects are anti-dilutive. Common stock equivalents comprising shares underlying 12,425,800 options and warrants for the three and nine months ended September 30, 2015 have not been included in the loss per share calculations as the effects are anti-dilutive.

Recent Accounting Pronouncements

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of adoption of ASU 2016-15.

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, “Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting,” which relates to the accounting for employee share-based payments. This standard addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification flows of awards as either equity or liabilities; and (c) classification on the statement of cash flows. This standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is in the process of evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements.

In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement on its consolidated financial statements.

In May 2014, the Financial Accounting Standards Board ("FASB") issued accounting guidance, "Revenue from Contracts with Customers." The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal year 2018. The Company is currently evaluating the impact this guidance will have on the consolidated financial statements.

Immudyne, Inc.

Notes to Consolidated Financial Statements

September 30, 2016

(unaudited)

2.	Summary of Significant Accounting Policies (continued)

Recent Accounting Pronouncements (continued)

In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-11, “Simplifying the Measurement of Inventory.” ASU 2015-11 applies to inventory that is measured using first-in, first-out (FIFO) or average cost. An entity should measure inventory within the scope of ASU 2015-11 at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016. The Company is in the process of evaluating the impact of this ASU on its consolidated financial statements.

In August 2014, the FASB issued ASU 2014-15, "Presentation of Financial Statements-Going Concern". This ASU is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. It is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The Company does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows.

All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.

Fair Value of Financial Instruments

The carrying value of the Company’s financial instruments, including cash, trade accounts receivable and accounts payable and accrued expenses and the face amount of notes payable approximate fair value for all periods.

Noncontrolling Interests

The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest’s share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.

Concentration of Credit Risk

The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.

The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.

Immudyne, Inc.

Notes to Consolidated Financial Statements

September 30, 2016

(unaudited)

2.	Summary of Significant Accounting Policies (continued)

Concentration of Credit Risk (continued)

One customer in the nutraceutical and cosmetic additives division accounted for 13% and 81% of consolidated sales for each of the three month periods ended September 30, 2016 and 2015, respectively. This customer accounted for 15% and 83% of consolidated sales for the nine month periods ended September 30, 2016 and 2015, respectively. This customer accounted for 0% and 43% of accounts receivable at September 30, 2016 and December 31, 2015, respectively.

A second customer in the nutraceutical and cosmetic additives division accounted for 3% and 13% of consolidated sales for each of the three month periods ended September 30, 2016 and 2015, respectively. This customer accounted for 2% and 13% of consolidated sales for the nine month periods ended September 30, 2016 and 2015, respectively. This customer accounted for 0% and 24% of accounts receivable at September 30, 2016 and December 31, 2015, respectively.

3.	Notes Payable

The Company periodically borrows from officers, directors, other related individuals and from commercial lenders. In November 2015 the Company borrowed $100,000 from a commercial lender. The loan incurs interest at 11% and is payable on November 1, 2016 (See Note 9). Interest expense related to this loan for the three and nine months ended September 30, 2016 amounted to $2,750 and $8,250, respectively. During the three and nine months ended September 30, 2015 interest expense related to a loan from a second commercial lender amounted to $5,175 and $23,517, respectively.

In the third quarter of 2016 the Company commenced an offering pursuant to which it offered 11% subordinated promissory notes due in six (6) months in fifty thousand ($50,000) dollar increments combined with 62,500 shares of the Company’s Common Stock for a maximum offering amount of $200,000 (the “Offering”). In August and September 2016, the Company sold promissory notes totaling $150,000 to three unrelated individuals. Two of the promissory notes totaling $100,000 are payable in February 2017 and one promissory note for $50,000 is payable in March 2017. In connection with these promissory notes sold pursuant to the Offering, the Company issued 187,500 shares of common stock valued at $41,875 which was recorded as a debt discount and will be amortized over the term of these notes. Amortization of the debt discounts for the three and nine months ended September 30, 2016 was $5,990. As of September 30, 2016, the outstanding balance of these notes were $150,000. Interest expense related to these notes for the three months ended September 30, 2016 amounted to $1,253.

Interest expense related to loans from officers, directors and other related individuals amounted to $313 and $9,531 for the nine month periods ended September 30, 2016 and 2015, respectively. Interest expense amounted to $0 and $9,247 for the three months ended September 30, 2016 and 2015, respectively.

Total interest expense on notes payable, inclusive of amortization of debt discount of $5,990 and $0, amounted to $15,805 and $33,048 for the nine months ended September 30, 2016 and 2015, respectively. Total interest expense, inclusive of amortization of debt discount of $5,990 and $0, amounted to $9,992 and $14,422 for the three months ended September 30, 2016 and 2015, respectively.

4.	Income Taxes

The Company is not expected to have taxable income in 2016 and incurred a loss for the year ended December 31, 2015 and accordingly, no provision for federal income tax has been made in the accompanying financial statements. At December 31, 2015, the Company had available net operating loss carryforwards of approximately $2,730,000, expiring during various years through 2035.

A summary of the deferred tax asset using an approximate 34% tax rate is as follows:

Deferred Tax Asset	$	930,000
Valuation allowance		(930,000	)
Total	$	-

The net operating loss carryforwards could be subject to limitation in any given year in the event of a change in ownership as defined by IRC Section 382.

The deferred tax benefit included in the 2015 statement of operations represents the change in the deferred tax liability at each balance sheet date.

The difference between the statutory and the effective tax rate is primarily due to a change in valuation allowance on deferred taxes, as the Company has fully reserved the deferred tax asset resulting from available net operating loss carryforwards.

Immudyne, Inc.

Notes to Consolidated Financial Statements

September 30, 2016

(unaudited)

5.	Stockholders’ Equity

On April 1, 2016, the Company entered into two agreements with two consultants to provide services over a nine month period in exchange for 2,300,000 shares of common stock. The Company calculated a fair value of $690,000 based on the market price of the shares on the date of the agreements. During the third quarter of 2016, the Company and the consultants renegotiated the agreements by extending the service requirement to December 31, 2017. For the three and nine months ended September 30, 2016, the Company has recognized expense of $76,667 and $306,667, respectively, in connection with these agreements.

On September 1, 2016, the Company issued 200,000 shares of common stock for $46,000. In connection with this issuance the Company issued 100,000 warrants with an exercise price of $0.50 per share. These warrants are fully vested and expire in two years.

In August 2016, the Company issued 125,000 shares of common stock pursuant to sale of two promissory notes in the Offering.

In September 2016, the Company issued 62,500 shares of common stock pursuant to the sale of one promissory note in the Offering.

In the third quarter of 2016, the Company purchased 19,363 shares of outstanding Company common stock through an exchange for a price per share of $0.23 to $0.26. As of the September 30, 2016, these shares being held by the Company valued at cost is $4,720 and are included in treasury stock in the consolidated balance sheet.

Service-Based Stock Options

In May 2016, the Company issued 175,000 service-based options valued at $40,829 to two consultants at exercise prices of $0.20 per share. The options are fully vested and expire in 10 years.

In July 2016, the Company issued 50,000 service-based options valued at $12,398 to a consultant with an exercise price of $0.20 per share. The options are fully vested and expire in 10 years.

Accordingly, stock based compensation for the three and nine months ended September 30, 2016 included $12,398 and $53,227, respectively, related to such options.

A Summary of the outstanding service-based options are as follows:

	Number of Options
Balance at December 31, 2015		11,025,273
Cancelled		(250,000	)
Issued		225,000

Balance at September 30, 2016		11,000,273

All outstanding options are exercisable and have a cashless exercise provision, and certain options provide for accelerated vesting provisions and modifications, as defined, if the Company is sold or acquired. The intrinsic value of options outstanding and exercisable at September 30, 2016 amounted to $750,294.

The significant assumptions used to determine the fair values of options issued, using a Black-Scholes option-pricing model are as follows:

Significant assumptions :
Risk-free interest rate at grant date		0.78% - 1.88	%
Expected stock price volatility		222.9% - 248.4	%
Expected dividend payout		—
Expected option life-years		2 - 3
Weighted average grant date fair value	$	0.22 - 0.26
Forfeiture rate		0	%

Immudyne, Inc.

Notes to Consolidated Financial Statements

September 30, 2016

(unaudited)

5.	Stockholders’ Equity (continued)

Service-Based Stock Options (continued)

The following is a summary of outstanding service-based options at September 30, 2016:

Exercise Price	Number of Options		Weighted Average Remaining Contractual Life

$0.10		1,680,273		2 years
$0.20 - $0.25		8,170,000		6 years
$0.40		1,150,000		5 years
Total		11,000,273

Performance-Based Stock Options

The Company had granted performance-based options to purchase 4,400,000 shares of common stock at exercise prices of $0.40 to $0.80. The options expire at various dates between 2021 and 2026 and are exercisable upon the Company achieving annual sales revenue of $5,000,000 and $10,000,000. The fair value of these performance-based options aggregated $169,035 to be expensed over the implicit service period commencing once management believes the performance criteria will be met.

Management believes the performance criteria for options exercisable upon the Company achieving annual sales revenue of $5,000,000, with a fair value amounting to $133,324, will be met during the year ended December 31, 2016. Accordingly, stock based compensation expense for the three and nine months ended September 30, 2016 includes $55,591 and $133,324, respectively, related to such options. At September 30, 2016, the unearned compensation for all the performance based options is $35,711.

Stock based compensation expense amounted to $165,241 and $10,500 for the three month periods ended September 30, 2016 and 2015, respectively. Stock based compensation expense amounted to $513,804 and $14,500 for the nine month periods ended September 30, 2016 and 2015, respectively. Such amounts are included in compensation and related expenses in the accompanying statement of operations.

Warrants

In September 2016, the Company issued 100,000 warrants with an exercise price of $0.50 per share, in relation to a sale of common stock. These warrants are fully vested and expire in two years.

In September 2016, the Company issued 100,000 warrants with exercise prices between $0.20 and $0.50 per share, for consulting services. These warrants are fully vested and expire in three years. The fair value of these warrants are $20,585 and is included in compensation and related expenses in the accompanying statement of operations.

Warrants outstanding and exercisable amounted to 1,950,000 and 1,750,000 at September 30, 2016 and December 31, 2015, respectively. The weighted average exercise price of warrants outstanding at September 30, 2016 is $0.19. The warrants expire during November 2016 and September 2019.

Immudyne, Inc.

Notes to Consolidated Financial Statements

September 30, 2016

(unaudited)

6.	Royalties

The Company was subject to a royalty agreement based upon sales of certain skin care products. The agreement required the Company to pay a royalty based upon 8% of such sales, up to $227,175. During the year ended December 31, 2015 the Company’s sales reached the maximum amount under which the Company was required to pay a royalty under this agreement. No royalty expense was recognized for the three month periods ended September 30, 2016 and 2015, respectively. Royalty expense amounted to $-0- and $20,157 for the nine month periods ended September 30, 2016 and 2015, respectively. During December 2015, the Company’s President who had a 60% interest in the royalties, converted royalties payable under the agreement in the amount of $84,868 to 499,225 shares of Company stock at $0.17 cents per share.

Included in accounts payable and accrued expenses at September 30, 2016 and December 31, 2015 was $56,579 in regards to this agreement.

7.	Commitments and Contingencies

Leases

The Company leases a plant in Kentucky under an operating lease which expired on May 31, 2016. Management is currently discussing renewal lease options for the Kentucky plant and is operating on a month-to-month lease arrangement until a final agreement has been accepted. Monthly base rental payments are approximately $9,000. In addition, Immudyne PR operates in Puerto Rico in space owned by one of the parties to the joint venture. Rent expense for the three month periods ended September 30, 2016 and 2015, was $27,706 and $15,286, respectively. Rent expense for the nine month periods ended September 30, 2016 and 2015, was $71,606 and $50,350, respectively.

Employment and Consulting Agreements

The Company has entered into various agreements with officers, directors, employees and consultants that expire in one to five years. The agreements provide for annual compensation of up to $145,000 and the issuance of stock options, at exercise prices of $0.40 and $0.80, to purchase 4,400,000 shares of common stock issuable upon the Company’s revenue exceeding $5,000,000 and $10,000,000, as defined. In addition, the agreements provide for bonus compensation to these individuals aggregating up to 15% (with no individual having more than 5%) of the Company’s pretax income.

Restricted Stock and Options

The Company has entered into two agreements on April 1, 2016 with two consultants of Immudyne PR for business development, marketing and sales related services (the “Consultant Agreements”). The consultants are treated as employees for accounting purposes. Upon signing, each consultant was issued 1,000,000 restricted shares of Immudyne, Inc. common stock. In addition, each consultant shall receive an additional 150,000 restricted shares of Immudyne, Inc. common stock for each $500,000 distributed by Immudyne PR to the Company. For each consultant the amount of shares to be issued by the Company to the consultants shall be capped at 1,500,000 restricted shares when Immudyne PR has transferred $5,000,000 to the Company, for a combined capped total of 3,000,000 restricted shares. For the three and nine months ended September 30, 2016, 2,300,000 restricted shares of common stock have been issued related to these agreements. The Company valued the shares at their grant date for a value of $0.30 per share for a total of $690,000 to be expensed over the estimated service period ending December 31, 2017.

Immudyne, Inc.

Notes to Consolidated Financial Statements

September 30, 2016

(unaudited)

7.	Commitments and Contingencies (continued)

Restricted Stock and Options (continued)

In addition, the Consulting Agreements provided that each consultant shall receive a bonus of an additional 750,000 restricted shares of Immudyne Inc. common stock, plus an option to buy 1,000,000 shares of Immudyne, Inc. common stock at $0.20/share (including a cashless exercise feature) when Immudyne PR has transferred to the Company at each of the following three (3) thresholds: $1,250,000, $2,000,000 and $3,000,000 for a total of 2,250,000 of restricted shares of Immudyne, Inc. common stock and options to purchase up to 3,000,000 shares of Immudyne, Inc. common stock at $0.20/share. As of September 30, 2016, no bonus shares have been issued and no options have been granted under this agreement.

Legal Matters

In the normal course of business operations the Company may become involved in various legal matters. At September 30, 2016, the Company’s management does not believe that there are any potential legal matters that could have an adverse effect on the Company’s financial position.

8.	Related Party Transactions

For the three and nine months ended September 30, 2016 one of the Company’s directors, acting as an advisor for the Company, provided legal and business advisory services and was compensated $6,000 and $15,000, respectively. During 2015 there was no compensation to this director. In addition, for the three and nine months ended September 30, 2016 the Company’s President received $6,000 and $20,000, respectively, for reimbursement of home office expenditures, including rent, utilities and other related expenses for two offices. During 2015 the Company’s president was not reimbursed for home office expenditures.

9.	Subsequent Events

The Company has evaluated subsequent events through the date these financial statements were issued. In October 2016, the Company made principle payments amounting to $18,800 on the outstanding promissory notes. In November 2016, the Company repaid the outstanding balance of the $100,000 commercial lender note. In October 2016, the Company sold an additional unit of the Offering borrowing $50,000 and issuing 62,500 of common stock. In October 2016, the Company purchased 27,637 shares of Company common stock at a cost of $7,382.

* * * * *

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We manufacture, distribute and sell natural immune support products; namely proprietary yeast beta glucans which are natural extracts that have been shown through testing and analysis and scientific research to support the immune system. Yeast beta glucans are classified as generally recognized as safe (“GRAS”) by the Food and Drug Administration (“FDA”). We are and have been a science driven company for more than 25 years. Our products are used in oral and topical applications. Historically, we have sold our proprietary additives, for both oral and topical use, primarily via business-to-business to large dietary supplement and cosmetic companies. During fiscal year 2015 we have seen increased interest in our proprietary GRAS topical delivery system, which we believe may have additional beneficial and marketable uses (both topically and orally) and on which are conducting further testing. In addition, during the fourth quarter of 2015, we established a joint venture, that does business under the name Inate Scientific LLC (“Inate”), to launch a complete skin care regimen that contains our proprietary ingredients and which contributed to our revenues in the first nine months of 2016. The Company entered into a limited liability company operating agreement with its joint venture partners with respect to Inate under the legal name Immudyne PR LLC (“Immudyne PR”). On April 1, 2016, the original operating agreement was amended and restated and we increased our ownership and voting interest in Immudyne PR to 78.16667%. As a result of our ownership and control of Immudyne PR, we now operate in two business segments, nutraceutical and cosmetic additives and finished cosmetic products.

We have performance based contracts with our sales and marketing executives, which allows us to continue to maintain a relatively low overhead. Our priority is to pursue opportunities to market our products and increase sales. We expect that a significant component of our selling, general and administration expenses going forward will consist of equipment leasing costs relating to improving our operating efficiencies, as well as conducting new studies which could open new markets. These aforementioned costs, along with the additional costs resulting from our operations as a public reporting company, could adversely impact our future results of operations. Additional significant factors that we believe will affect our operating results going forward are: (i) protection of our intellectual property rights; (ii) imposition of more stringent government regulations of our products; and (iii) marketing expenses.

We historically have expended a significant amount of our funds on obtaining and protecting our patents, trade secrets and proprietary products. We rely on the patent and trademark protection laws in the U.S. to protect our intellectual property and maintain our competitive position in the marketplace. For several years, we were involved in complex litigation regarding patents and licenses critical to our products. In 2010, we prevailed on all major legal matters and reached favorable settlements. If additional litigation becomes necessary to protect our intellectual property rights, such litigation may be costly, divert our management’s attention away from our core business and have a negative impact on our operations. Furthermore, there is no guarantee that litigation would result in an outcome favorable to us. In addition, yeast beta glucans are designated as GRAS under current FDA regulations. Future government regulations may prevent or delay the introduction or require the reformulation of our products. Some agencies, such as the FDA, could require us to remove a particular product from the market, delay or prevent the import of raw materials for the manufacture of our products or otherwise disrupt the marketing of our products. Any such government actions could result in additional costs to us, reduced growth prospects, lost sales from products that we are required to remove from the market and potential product liability litigation.

We have historically operated with limited capital and have funded operations in the past through the sales of our products and loans and advances from Mark McLaughlin, our President, and other directors. In 2015 we entered into a non-dilutive short term loan agreement with an investor for $100,000 and secured additional loans of $30,000 from our President and $75,000 from a greater than 5% shareholder of the Company. These loans were satisfied in full as of December 31, 2015. In addition, in November 2015, we established a $100,000 line of credit with a commercial lender for our short-term working capital needs, which has since been repaid in full. In the third quarter of 2016 the Company sold $150,000 of 11% subordinated promissory notes due in six (6) months in fifty thousand ($50,000) dollar increments combined with 62,500 shares of the Company’s common stock. We plan on our operating business (in conjunction with our short term non-dilutive borrowings) to be able to fund operations through 2016. However, in the event we require additional operating capital we may have to depend on sources other than operating revenues to meet our operating and capital needs. No assurance can be given that such sources will be available and no assurance can be given that Mr. McLaughlin or other directors who have in the past willingly funded operations will commit to do so in the future, or that we will be successful in our endeavors to raise additional capital. For additional information regarding these and other risks please see our Annual Report on Form 10K for the fiscal year ended December 31, 2015 filed with the SEC on March 30, 2016.

Results of Operations

Three Months Ended September 30, 2016, Compared to the Three Months Ended September 30, 2015

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales:

	2016						2015
	$			*% of Sales*			$			*% of Sales*
Sales		1,384,429						279,883
Cost of sales		942,738			68	%		73,988			26	%
Gross profit		441,691			32	%		205,895			74	%
Operating expenses		(649,395	)		(47	)%		(187,954	)		(67	)%
(Loss) Income from operations		(207,704	)		(15	)%		17,941			6	%
Interest (expense)		(9,992	)		(1	)%		(14,422	)		(5	)%
Income tax benefit		-			0	%		4,600			2	%
Net income (loss)		(217,696	)		(16	)%		8,119			3	%
Net income (loss) attributable to noncontrolling interests		8,955			1	%		-			0	%
Net income (loss) attributable to Immudyne, Inc.		(226,651	)		(16	)%		8,119			3	%

Overall sales for the three months ended September 30, 2016 were $1.38 million, an increase of 395% from $0.28 million for the same period in 2015. Our increase in sales was primarily attributable to sales made by our finished cosmetic products segment of $1.15 million through our joint venture with Inate, which did not operate in the period ended September 30, 2015. Net sales for our nutraceutical and cosmetic additives segment remained relatively consistent between periods at $0.22 million and were in line with our expectations.

Cost of sales consists primarily of material costs, labor costs, marketing costs and related overhead directly attributable to the production of our products. Total cost of sales increased 1174% to $0.94 million in the third quarter of 2016 compared to $0.07 million for the same period in 2015, which costs in the 2015 period were solely attributable to our nutraceutical and cosmetic additives product segment. The increase in our cost of sales was due to our increased advertising and marketing expenses incurred to generate our increase in sales from our finished cosmetic products segment, which costs were not incurred in the third quarter of 2015.

Gross profit increased 155% to $0.44 million in the third quarter of 2016 compared to $0.20 million for the same period in 2015 as a result of our increased sales offset by our advertising and marketing expenses for the quarter. Gross profit as a percentage of sales decreased to 32% in the third quarter of 2016 from 74% for the same period in 2015 due to the shift in the composition of our sales between periods from solely topical and oral additives to primarily finished products sold through Inate, which products generally have lower margins.

Operating expenses consisted of general and administrative expense, compensation and related expense and professional fees. Overall operating expenses increased 246% to $0.65 million in the third quarter of 2016 from $0.19 million for the same period in 2015, primarily due to increased compensation related expenses with respect to shares issued to the Company’s joint venture partners pursuant to previously disclosed service agreements. The increase in our overall operating expenses was also due to our increase in sales. General and administration expense increased 256% to $0.20 million in the third quarter of 2016 from $0.06 million for the same period in 2015. Compensation and related expense increased 258% to $0.36 million in the third quarter of 2016 from $0.10 million for the same period in 2015 due to the aforementioned share issuance. Professional fees increased 183% to $0.08 million in the third quarter of 2016 from approximately $0.03 million for the same period in 2015, due to increased legal and accounting fees incurred with respect to Inate’s operations.

Net loss attributable to Immudyne in the third quarter of 2016 was approximately $0.27 million compared to net income of $0.01 million for the same period in 2015. We consolidated the operations of our joint venture, Inate, and reflected a non-controlling interest for 21.833% of these operations. Net loss attributable to Immudyne, Inc. as a percentage of sales was 16% in the third quarter of 2016 compared to net income as a percentage of sales of 3% for the same period in 2015. Our net loss notwithstanding our substantial increase in sales was primarily due to the advertising and marketing expenses we incurred in the quarter to help generate sales and our increased compensation expenses due to shares issued to the Company’s joint venture partners pursuant to previously disclosed service agreements. We believe these costs will decrease as a percentage of sales over the course of the fiscal year as Inate continues to mature as a business.

Nine Months Ended September 30, 2016, Compared to the Nine Months Ended September 30, 2015

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales:

	2016						2015
	$			*% of Sales*			$			*% of Sales*
Sales		4,252,704						845,513
Cost of sales		2,981,657			70	%		237,707			28	%
Gross profit		1,271,047			30	%		607,806			72	%
Operating expenses		(1,737,479	)		(41	)%		(599,201	)		(71	)%
(Loss) Income from operations		(466,432	)		(11	)%		8,605			(1	)%
Interest (expense)		(15,805	)		0	%		(33,048	)		(4	)%
Income tax benefit		-			0	%		13,200			2	%
Net loss		(482,237	)		(11	)%		(11,243	)		(1	)%
Net income attributable to noncontrolling interest		6,439			0	%		-			0	%
Net loss attributable to Immudyne, Inc.		(488,676	)		(11	)%		(11,243	)		(1	)%

Overall sales for the nine months ended September 30, 2016 were $4.25 million, an increase of 403% from $0.85 million for the same period in 2015. Our increase in sales was primarily attributable to sales made by our finished cosmetic products segment of $3.49 million through our joint venture with Inate, which did not operate in the period ended September 30, 2015. Net sales for our nutraceutical and cosmetic additives segment remained relatively consistent between periods at $0.78 million and were in line with our expectations.

Cost of sales consists primarily of material costs, labor costs, marketing costs and related overhead directly attributable to the production of our products. Total cost of sales increased 1,154% to $2.98 million for the nine months ended September 30, 2016 compared to $0.24 million for the same period in 2015, which costs in the 2015 period were solely attributable to our nutraceutical and cosmetic additives product segment. The increase in our cost of sales was due to our significant up-front advertising and marketing expenses ($1.71 million) incurred to generate our significant increase in sales from our finished cosmetic products segment, which costs were not incurred in the 2015 period.

Gross profit increased 109% to $1.27 million in the nine months ended September 30, 2016 compared to $0.61 million for the same period in 2015 as result of our increased sales offset by our significant up-front advertising and marketing expenses in the 2016 period. Gross profit as a percentage of sales decreased to 30% for the nine months ended September 30, 2016 from 72% for the same period in 2015 due to the shift in the composition of our sales between periods from solely topical and oral additives to primarily finished products through Inate, which products generally have lower margins.

Operating expenses consisted of general and administrative expense, compensation and related expense and professional fees. Overall operating expenses increased 190% to $1.74 million in the nine months ended September 30, 2016 from $0.60 million for the same period in 2015. The increase in our overall operating expenses was due primarily to our operation of Inate in the 2016 year whereas we only had operations in our nutraceutical and cosmetic additives segment in the comparable 2015 period. General and administration expense increased 85% to $0.38 million for the nine months ended September 30, 2016 from $0.21 million for the same period in 2015. Compensation and related expense increased 258% to $1.08 million in the nine months ended September 30, 2016 from $0.30 million for the same period in 2015 due primarily to increased compensation related expenses with respect to shares issued to the Company’s joint venture partners pursuant to previously disclosed service agreements. Professional fees increased 205% to $0.27 million for the nine months ended September 30, 2016 from approximately $0.09 million for the same period in 2015, due to increased legal and accounting fees incurred with respect to Inate’s operations.

Net loss attributable to Immudyne in the nine months ended September 30, 2016 was approximately $0.49 million compared to net loss of $0.01 million for the same period in 2015. We consolidated the operations of our joint venture, Inate, and reflected a non-controlling interest for 21.833% of these operations. Net loss attributable to Immudyne, Inc. as a percentage of sales was 11% in nine months ended September 30, 2016 compared to net loss as a percentage of sales of 1% for the same period in 2015. Our net loss notwithstanding our substantial increase in sales was primarily due to the substantial up-front advertising and marketing expenses we incurred to help generate sales through our recently formed joint venture, Inate, and our increased compensation expenses due to shares issued to the Company’s joint venture partners pursuant to previously disclosed service agreements. We believe these costs will decrease as a percentage of sales as Inate continues to mature as a business.

Liquidity and Capital Resources

Our principal demands for liquidity are to increase sales, purchase inventory and for sales distribution and general corporate purposes. We incurred negative operating cash flows in the 2015 and 2014 fiscal years and for the first three quarters of 2016. As a result, our auditors have raised substantial doubt about our ability to continue as a going concern. We plan on our operating business (in conjunction with our short term non-dilutive borrowings) being able to fund operations through 2016. However, if necessary, we may raise additional capital through a private placement of common stock, obtaining debt financing or from advances from our President and/or directors; however, no assurances can be made that we will be successful in our endeavors to raise additional capital.

In 2015 we entered into a non-dilutive short term loan agreement with an investor for $100,000 and secured additional loans of $30,000 from our President and $75,000 from a greater than 5% shareholder of the Company. These loans were satisfied in full as of December 31, 2015. In addition, in November 2015, we secured a $100,000 line of credit with a commercial lender for our short-term working capital needs, which has since been repaid in full. In the third quarter of 2016 the Company sold $150,000 of 11% subordinated promissory notes due in six (6) months in fifty thousand ($50,000) dollar increments combined with 62,500 shares of the Company’s common stock.

There can be no assurance that required future financing can be successfully completed on a timely basis, or on terms acceptable to us. Any future issuance of equity securities could cause dilution to our shareholders. Any incurrence of indebtedness would increase our debt service obligations and would cause us to be subject to restrictive operating and financial covenants.

We had net working capital of approximately $457,066 at September 30, 2016, resulting in an increase from net working capital of approximately ($136,841) at September 30, 2015. The ratio of current assets to current liabilities was 1.7 to 1 at September 30, 2016.

The following is a summary of cash provided by or used in each of the indicated types of activities during the nine months ended September 30, 2016 and 2015:

	2016			2015
Cash provided by (used in):
Operating activities	$	(111,698	)	$	(80,311	)
Financing activities		352,635			78,678

Net cash flow used by operating activities was $0.11 million for the nine months ended September 30, 2016, compared to net cash flow used in operating activities of $0.08 million for the same period in 2015. The increase in the amount of cash used by our operating activities was due to up-front advertising and marketing expenses incurred in the 2016 period. We expect that these expenses will decrease as a percentage of sales over the course of the fiscal year as Inate continues to mature as a business.

Net cash flows provided by financing activities was $0.35 million for the nine months ended September 30, 2016, compared to net cash flows provided by financing activities of $0.08 million for the same period in 2015 due to additional indebtedness incurred during the period as further described below.

Indebtedness

From time to time, our directors, officers and other related individuals have made short-term advances to us for our operating needs. In 2015 we entered into a non-dilutive short term loan agreement with an investor for $100,000 and secured additional loans of $30,000 from our President and $75,000 from a greater than 5% shareholder of the Company. These loans were satisfied in full as of December 31, 2015. In addition, in November 2015, we secured a $100,000 line of credit with a commercial lender for our short-term working capital needs, which has since been repaid in full. In the third quarter of 2016 the Company sold $150,000 of 11% subordinated promissory notes due in six (6) months in fifty thousand ($50,000) dollar increments combined with 62,500 shares of the Company’s Common Stock.

We are subject to a royalty agreement pursuant to which we are required to pay a monthly royalty of 8% on all sales of certain skin care products up to $227,175. During the year ended December 31, 2015 our sales reached the maximum amount under which we are required to pay a royalty under this agreement. Royalty expense amounted to $0 and $20,157 for the nine months ended September 30, 2016 and 2015, respectively. During 2015, our President, who has a 60% interest in the royalties, converted all royalties payable (in the amount of $84,868) to 499,225 shares of the company’s stock valued at $0.17 cents a share.

Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to shareholders.

We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as stockholders’ equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

Critical Accounting Policies

While our significant accounting policies are described more fully in Note 2 to our financial statements, we believe the following accounting policies are the most critical to aid you in fully understanding and evaluating this management discussion and analysis.

Basis of Presentation and Use of Estimates

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the U.S., or U.S. GAAP. In preparing financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates required by management include the valuation of inventory and stockholders’ equity-based transactions. Actual results could differ from those estimates.

Inventory

Inventory is valued at the lower of cost or market value with cost determined on a first-in, first-out basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down their inventories to market value, if lower.

Revenue Recognition

Delivery is considered to have occurred when title and risk of loss have transferred to the customer. If title does not pass until the product reaches the customer’s delivery site, then recognition of revenue is deferred until that time. There are no formal sales incentives offered to any of the Company’s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis.

Stock-based Compensation

The Company follows the provisions of ASC 718, “Share-Based Payment”. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of our shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, estimated forfeiture rate included in the option valuation was zero. Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.

Noncontrolling Interests

The Company accounts for its less than 100% interest in Inate in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest’s share of Inate net loss attributable to noncontrolling interests in the consolidated statement of operations.

New Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, “Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting,” which relates to the accounting for employee share-based payments. This standard addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. This standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is in the process of evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

Item 4.

Controls and Procedures

Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer (“PEO”), who is also our Principal Financial Officer (“PFO”), of the design and effectiveness of our “disclosure controls and procedures” (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on this evaluation, our PEO/PFO concluded that as of the end of the period covered by this report, these disclosure controls and procedures were not effective. The conclusion that our disclosure controls and procedures were not effective was due to the presence of the following material weaknesses in disclosure controls and procedures which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment as the Company had only one officer; (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC Guidelines; and (iii) inadequate security and restricted access to computer systems including insufficient disaster recovery plans; and (iv) no written whistleblower policy. If and when sufficient funds are available, our PEO/PFO plans to implement appropriate disclosure controls and procedures to remediate these material weaknesses, including (i) appointing additional qualified personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopt sufficient written policies and procedures for accounting and financial reporting and a whistle blower policy; and (iii) implement sufficient security and restricted access measures regarding our computer systems and implement a disaster recovery plan.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended September 30, 2016, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

We may become involved in various lawsuits and legal proceedings arising in the ordinary course of business. Litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may have an adverse effect on our business, financial conditions or operating results. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

Item 1A.

Risk Factors

You should consider carefully the factors discussed in the “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

On September 1, 2016, the Company issued 200,000 shares of common stock for $46,000 pursuant to Section 4(a)(2) of the Securities Act. In connection with this issuance the Company issued 100,000 warrants with an exercise price of $0.50 per share. These warrants are fully vested and expire in two years.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

None.

Item 6.

Exhibits

See the Exhibit Index following the signature page to this Quarterly Report on Form 10-Q for a list of exhibits filed or furnished with this report, which Exhibit Index is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	IMMUDYNE INC.
	(Registrant)

Date: November 14, 2016	By:	/s/ Mark McLaughlin
		Mark McLaughlin
		Chief Executive Officer
		(Principal Executive Officer)

EXHIBIT INDEX

Exhibit No.		Document Description
31.1 †		Certification of Principal Executive Officer and Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 ‡		Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS†		XBRL Instance Document
101.SCH†		XBRL Schema Document
101.CAL†		XBRL Calculation Linkbase Document
101.DEF†		XBRL Definition Linkbase Document
101.LAB†		XBRL Label Linkbase Document
101.PRE†		XBRL Presentation Linkbase Document

† Filed herewith

‡ Furnished herewith

EX-31.1 2 f10q0916ex31i_immudyneinc.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302(a)

OF THE SARBANES-OXLEY ACT OF 2002

I, Mark McLaughlin, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2016, of Immudyne, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2016	By:	/s/ Mark McLaughlin
		Mark McLaughlin
		(Principal Executive Officer and Principal Financial Officer)

EX-32.1 3 f10q0916ex32i_immudyneinc.htm CERTIFICATION

Exhibit 32.1

CERTIFICATIONS OF PRESIDENT AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark McLaughlin, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Immudyne, Inc. for the quarterly period ended September 30, 2016, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Immudyne Inc.

Date: November 14, 2016	By:	/s/ Mark McLaughlin
		Mark McLaughlin
		(Principal Executive Officer and Principal Financial Officer)

EX-101.INS 4 immd-20160930.xml XBRL INSTANCE FILE 0000948320 2014-12-31 0000948320 2015-07-01 2015-09-30 0000948320 us-gaap:AccountsReceivableMember immd:OneCustomerMember immd:NutraceuticalAndCosmeticMember 2015-07-01 2015-09-30 0000948320 us-gaap:AccountsReceivableMember immd:SecondCustomerMember immd:NutraceuticalAndCosmeticMember 2015-07-01 2015-09-30 0000948320 us-gaap:BoardOfDirectorsChairmanMember 2015-07-01 2015-09-30 0000948320 immd:NutraceuticalAndCosmeticMember 2015-07-01 2015-09-30 0000948320 immd:CosmeticGoodsMember 2015-07-01 2015-09-30 0000948320 us-gaap:IntersegmentEliminationMember 2015-07-01 2015-09-30 0000948320 us-gaap:SalesMember immd:OneCustomerMember immd:NutraceuticalAndCosmeticMember 2015-07-01 2015-09-30 0000948320 us-gaap:SalesMember immd:SecondCustomerMember immd:NutraceuticalAndCosmeticMember 2015-07-01 2015-09-30 0000948320 immd:PerformanceBasedStockOptionsMember 2015-07-01 2015-09-30 0000948320 us-gaap:EmployeeStockOptionMember us-gaap:WarrantMember 2015-07-01 2015-09-30 0000948320 us-gaap:NotesPayableOtherPayablesMember 2015-07-01 2015-09-30 0000948320 2015-01-01 2015-09-30 0000948320 us-gaap:BoardOfDirectorsChairmanMember 2015-01-01 2015-09-30 0000948320 immd:NutraceuticalAndCosmeticMember 2015-01-01 2015-09-30 0000948320 immd:CosmeticGoodsMember 2015-01-01 2015-09-30 0000948320 us-gaap:IntersegmentEliminationMember 2015-01-01 2015-09-30 0000948320 us-gaap:SalesMember immd:OneCustomerMember immd:NutraceuticalAndCosmeticMember 2015-01-01 2015-09-30 0000948320 us-gaap:SalesMember immd:SecondCustomerMember immd:NutraceuticalAndCosmeticMember 2015-01-01 2015-09-30 0000948320 immd:PerformanceBasedStockOptionsMember 2015-01-01 2015-09-30 0000948320 us-gaap:EmployeeStockOptionMember us-gaap:WarrantMember 2015-01-01 2015-09-30 0000948320 us-gaap:NotesPayableOtherPayablesMember 2015-01-01 2015-09-30 0000948320 2015-09-30 0000948320 2015-11-30 0000948320 2015-11-02 2015-11-30 0000948320 2015-01-01 2015-12-31 0000948320 us-gaap:AccountsReceivableMember immd:OneCustomerMember 2015-01-01 2015-12-31 0000948320 us-gaap:AccountsReceivableMember immd:SecondCustomerMember 2015-01-01 2015-12-31 0000948320 us-gaap:PresidentMember 2015-01-01 2015-12-31 0000948320 2015-12-31 0000948320 immd:NutraceuticalAndCosmeticMember 2015-12-31 0000948320 immd:CosmeticGoodsMember 2015-12-31 0000948320 us-gaap:IntersegmentEliminationMember 2015-12-31 0000948320 us-gaap:PresidentMember 2015-12-31 0000948320 us-gaap:EmployeeStockOptionMember 2015-12-31 0000948320 us-gaap:WarrantMember 2015-12-31 0000948320 us-gaap:CommonStockMember 2015-12-31 0000948320 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000948320 us-gaap:RetainedEarningsMember 2015-12-31 0000948320 immd:SummationMember 2015-12-31 0000948320 us-gaap:NoncontrollingInterestMember 2015-12-31 0000948320 us-gaap:TreasuryStockMember 2015-12-31 0000948320 immd:ImmudynePrLlcMember 2016-04-01 0000948320 us-gaap:RestrictedStockMember 2016-03-25 2016-04-01 0000948320 immd:ConsultantMember 2016-03-25 2016-04-01 0000948320 us-gaap:EmployeeStockOptionMember 2016-05-01 2016-05-31 0000948320 us-gaap:EmployeeStockOptionMember 2016-07-20 2016-07-31 0000948320 us-gaap:IPOMember 2016-08-31 0000948320 2016-09-01 0000948320 2016-08-25 2016-09-01 0000948320 2016-07-01 2016-09-30 0000948320 us-gaap:AccountsReceivableMember immd:OneCustomerMember immd:NutraceuticalAndCosmeticMember 2016-07-01 2016-09-30 0000948320 us-gaap:AccountsReceivableMember immd:SecondCustomerMember immd:NutraceuticalAndCosmeticMember 2016-07-01 2016-09-30 0000948320 us-gaap:BoardOfDirectorsChairmanMember 2016-07-01 2016-09-30 0000948320 immd:NutraceuticalAndCosmeticMember 2016-07-01 2016-09-30 0000948320 immd:CosmeticGoodsMember 2016-07-01 2016-09-30 0000948320 us-gaap:IntersegmentEliminationMember 2016-07-01 2016-09-30 0000948320 us-gaap:SalesMember immd:OneCustomerMember immd:NutraceuticalAndCosmeticMember 2016-07-01 2016-09-30 0000948320 us-gaap:SalesMember immd:SecondCustomerMember immd:NutraceuticalAndCosmeticMember 2016-07-01 2016-09-30 0000948320 immd:PerformanceBasedStockOptionsMember 2016-07-01 2016-09-30 0000948320 us-gaap:EmployeeStockOptionMember us-gaap:WarrantMember 2016-07-01 2016-09-30 0000948320 us-gaap:NotesPayableOtherPayablesMember 2016-07-01 2016-09-30 0000948320 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0000948320 2016-01-01 2016-09-30 0000948320 us-gaap:BoardOfDirectorsChairmanMember 2016-01-01 2016-09-30 0000948320 immd:NutraceuticalAndCosmeticMember 2016-01-01 2016-09-30 0000948320 immd:CosmeticGoodsMember 2016-01-01 2016-09-30 0000948320 us-gaap:IntersegmentEliminationMember 2016-01-01 2016-09-30 0000948320 us-gaap:SalesMember immd:OneCustomerMember immd:NutraceuticalAndCosmeticMember 2016-01-01 2016-09-30 0000948320 us-gaap:SalesMember immd:SecondCustomerMember immd:NutraceuticalAndCosmeticMember 2016-01-01 2016-09-30 0000948320 immd:PerformanceBasedStockOptionsMember 2016-01-01 2016-09-30 0000948320 us-gaap:EmployeeStockOptionMember us-gaap:WarrantMember 2016-01-01 2016-09-30 0000948320 us-gaap:NotesPayableOtherPayablesMember 2016-01-01 2016-09-30 0000948320 us-gaap:AccountsReceivableMember immd:OneCustomerMember 2016-01-01 2016-09-30 0000948320 us-gaap:AccountsReceivableMember immd:SecondCustomerMember 2016-01-01 2016-09-30 0000948320 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0000948320 us-gaap:WarrantMember 2016-01-01 2016-09-30 0000948320 us-gaap:CommonStockMember 2016-01-01 2016-09-30 0000948320 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0000948320 us-gaap:RetainedEarningsMember 2016-01-01 2016-09-30 0000948320 immd:SummationMember 2016-01-01 2016-09-30 0000948320 us-gaap:NoncontrollingInterestMember 2016-01-01 2016-09-30 0000948320 us-gaap:RestrictedStockMember 2016-01-01 2016-09-30 0000948320 immd:PerformanceBasedStockOptionsMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0000948320 immd:PerformanceBasedStockOptionsMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0000948320 immd:ExercisePriceRangeOneMember 2016-01-01 2016-09-30 0000948320 immd:ExercisePriceRangeTwoMember 2016-01-01 2016-09-30 0000948320 immd:ExercisePriceRangeThreeMember 2016-01-01 2016-09-30 0000948320 us-gaap:TreasuryStockMember 2016-01-01 2016-09-30 0000948320 us-gaap:MaximumMember 2016-01-01 2016-09-30 0000948320 us-gaap:MinimumMember 2016-01-01 2016-09-30 0000948320 2016-09-30 0000948320 immd:NutraceuticalAndCosmeticMember 2016-09-30 0000948320 immd:CosmeticGoodsMember 2016-09-30 0000948320 us-gaap:IntersegmentEliminationMember 2016-09-30 0000948320 immd:PerformanceBasedStockOptionsMember 2016-09-30 0000948320 us-gaap:EmployeeStockOptionMember 2016-09-30 0000948320 us-gaap:WarrantMember 2016-09-30 0000948320 us-gaap:CommonStockMember 2016-09-30 0000948320 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0000948320 us-gaap:RetainedEarningsMember 2016-09-30 0000948320 immd:SummationMember 2016-09-30 0000948320 us-gaap:NoncontrollingInterestMember 2016-09-30 0000948320 us-gaap:IPOMember 2016-09-30 0000948320 immd:ExercisePriceRangeOneMember 2016-09-30 0000948320 immd:ExercisePriceRangeTwoMember 2016-09-30 0000948320 immd:ExercisePriceRangeThreeMember 2016-09-30 0000948320 us-gaap:TreasuryStockMember 2016-09-30 0000948320 us-gaap:MaximumMember 2016-09-30 0000948320 us-gaap:MinimumMember 2016-09-30 0000948320 immd:ExercisePriceRangeTwoMember us-gaap:MinimumMember 2016-09-30 0000948320 immd:ExercisePriceRangeTwoMember us-gaap:MaximumMember 2016-09-30 0000948320 us-gaap:WarrantMember us-gaap:MinimumMember 2016-09-30 0000948320 us-gaap:WarrantMember us-gaap:MaximumMember 2016-09-30 0000948320 us-gaap:SubsequentEventMember 2016-10-31 0000948320 us-gaap:SubsequentEventMember 2016-10-20 2016-10-31 0000948320 2016-11-14 0000948320 us-gaap:SubsequentEventMember 2016-11-30 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure immd:Consultants Immudyne, Inc. 0000948320 false --12-31 10-Q 2016-09-30 2016 Q3 Smaller Reporting Company 34760375

75495

73862

232984

473921

154436

474924

61051

130530

448471

1079375

167481

408194

100000

214115

267481

622309

320103

46000

346978

8366313

9032728

-8586338

-9075014

100078 304692

4720

100078

299972

80912

157094

180990

320103

8366313

-8586338

100078

80912

457066

346978

9032728

-9075014

299972

157094

-4720

448471

1079375

0.01

50000000

32010375

125000

200000

34697875

62500

32010375

34678512

19363

279883

845513

1384429

229741

1154688

4252704

780961

3494743

-23000

73988

237707

942738

2981657

205895

607806

441691

1271047

101137 301301 361829 1077340

29237

91059

82608

277282

57580

206841

204958

382857

187954

599201

649395

1737479

17941

8605

-207704

-466432

14422

33048

9992

1253

15805

3519

-24443

-217696

-482237

-4600

-13200

8119

-11243

-217696

-258713

-41017

-482237

-653757

171520

-488676

6439

8955

6439

8119

-11243

-226651

-488676

0.00

-0.00

-0.01

-0.02

30650000

30663306

34427087

31917873

30650000

30663306

34427087

31917873

32010375

34697875

133324 133324 133324

690000

306667

23000

283667

306667

2300000

46000

2000

44000

46000

7382

499225

200000

27637

41875

1875

40000

41875

187500

20585

91612

-91612

-4720

53227

161355

43748

-43558

5990

14500

55591

12398

493218

133324

53227

116754

276930

-1579

69479

1059

240713

-80311

-111698

161355

205000

150000

115522

46000

-10800

-4720

78678

352635

-1633

240937

24547

8563

10200

41875

581093

20585

<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"> <td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; text-align: justify; font-size-adjust: none; font-stretch: normal;">2.</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;">Summary of Significant Accounting Policies</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Unaudited Financial Statements <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for financial information and with the instructions to Form 10-Q. They do not include all information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The unaudited financial statements should be read in conjunction with those financial statements included in the Company’s previously filed Form 10-K for the year ended December 31, 2015. In the opinion of management, all adjustments considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Basis of Presentation and Use of Estimates <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The consolidated financial statements include the accounts of the Company and its controlled subsidiary, Immudyne PR. The non- controlling interest in Immudyne PR represents the 21.833% equity interest held by other members of the joint venture. All intercompany transactions have been eliminated. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the valuation of inventory and stockholders’ equity based transactions. Actual results could differ from those estimates. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Inventory <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">At September 30, 2016 and December 31, 2015, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic products. Inventory is maintained in the Company’s leased Kentucky warehouse and third party warehouses in Pennsylvania and Louisiana. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">   <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Inventory is valued at the lower of cost or market with cost determined on a first-in, first-out (“FIFO”) basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to market value, if lower. At September 30, 2016 and December 31, 2015, the Company recorded an inventory reserve in the amount of $20,000. Inventory consists of the following: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December 31, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td> </td> <td style="text-align: right;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: right;" colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 0.5in; background-color: white;"> </td> <td style="text-align: left;">Raw materials</td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">49,083</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">25,761</td> <td style="width: 15px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left; padding-bottom: 1.5pt;">Finished products</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">81,447</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">35,290</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 4pt;"> </td> <td style="padding-bottom: 4pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">130,530</td> <td style="text-align: left; padding-bottom: 4pt;"> </td> <td style="padding-bottom: 4pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">61,051</td> <td style="text-align: left; padding-bottom: 4pt;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Revenue Recognition <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company’s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer, and for sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped, but in limited cases if title does not pass until the product reaches the customer’s delivery site, then recognition of revenue is deferred until that time. Delivery is considered to have occurred when title and risk of loss have transferred to the customer. Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates approximated $530,000 and $1,578,000 in the three-month and nine-month periods ended September 30, 2016, respectively. Customer discounts, returns and rebates were not significant in the three-month and nine-month periods ended September 30, 2015. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Delivery is considered to have occurred when title and risk of loss have transferred to the customer. If title does not pass until the product reaches the customer’s delivery site or the customer accepts the product, then recognition of revenue is deferred until that time. There are no formal sales incentives offered to any of the Company’s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Revenue for the nine-month period ended September 30, 2016 consisted of nutraceutical and cosmetic additives ($757,961) and finished cosmetic products ($3,494,743). Revenue for the nine month period ended September 30, 2015 consisted solely of nutraceutical and cosmetic additives. Revenue for the three-month period ended September 30, 2016 consisted of nutraceutical and cosmetic additives ($229,741) and finished cosmetic products ($1,154,688). Revenue for the three month period ended September 30, 2015 consisted solely of nutraceutical and cosmetic additives. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Accounts receivable <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Accounts receivable are carried at original invoice amount less an estimate made for holdbacks and doubtful receivables based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers’ accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. At September 30, 2016 and December 31, 2015 the accounts receivable reserve was approximately $122,000 and $18,000, respectively. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">   <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Segments <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The guidance for disclosures about segments of an enterprise requires that a public business enterprise report financial and descriptive information about its operating segments. Generally, financial information is required to be reported on the basis used internally for evaluating segment performance and resource allocation. The Company manages its operations in two reportable segments for purposes of assessing performance and making operating decisions. Revenue is generated predominately in the United States, and all significant assets are held in the United States, or United States territories. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">A summary of the company’s reportable segments is as follows: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold;">Total assets:</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold;"> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December 31, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 0.5in; background-color: white;"> </td> <td style="text-align: left;">Nutraceutical and Cosmetic Additives</td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">519,646</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">412,324</td> <td style="width: 15px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Finished Cosmetic Products</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">695,205</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">101,828</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Eliminations</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(135,476</td> <td style="text-align: left; padding-bottom: 1.5pt;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(65,681</td> <td style="text-align: left; padding-bottom: 1.5pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;">Total</td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,079,375</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">448,471</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold;">Total sales:</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold;"> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Three months ended</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Nine months ended</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 0.5in; background-color: white;"> </td> <td style="text-align: left;">Nutraceutical and Cosmetic Additives</td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">229,741</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">279,883</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">780,961</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">845,513</td> <td style="width: 15px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Finished Cosmetic Products</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,154,688</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,494,743</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Eliminations</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(23,000</td> <td style="text-align: left; padding-bottom: 1.5pt;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;">Total</td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,384,429</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">279,883</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">4,252,704</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">845,513</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">Net (loss) income:</td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-size: 10pt;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="6">Three months ended</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="6">Nine months ended</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-size: 10pt;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2">September 30, 2016</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2">September 30, 2015</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2">September 30, 2016</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2">September 30, 2015</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 0.5in; background-color: white;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">Nutraceutical and Cosmetic Additives</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-size-adjust: none; font-stretch: normal;">(258,713</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;">)</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-size-adjust: none; font-stretch: normal;">8,119</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-size-adjust: none; font-stretch: normal;">(653,757</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;">)</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-size-adjust: none; font-stretch: normal;">(11,243</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">Finished Cosmetic Products</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">41,017</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">171,520</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">Eliminations</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">Total</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">$</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">(217,696</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">)</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">$</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">8,119</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">$</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">(482,237</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">)</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">$</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">(11,243</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">)</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">   <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">As of and for the nine months ended September 30, 2015, there were no assets, sales or net loss relative to the finished cosmetic products segment. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Income Taxes <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company files Corporate Federal and State tax returns, while Immudyne PR, which was formed as a limited liability corporation, files a separate tax return with any tax liabilities or benefits passing through to its members. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company records current and deferred taxes in accordance with Accounting Standards Codification (ASC) 740, “Accounting for Income Taxes.” This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company’s tax returns for all years since December 31, 2012, remain open to taxing authorities. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Stock-Based Compensation <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company follows the provisions of ASC 718, “Share-Based Payment”. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company’s shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">   <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Earnings (Loss) Per Share <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Common stock equivalents comprising shares underlying 12,950,273 options and warrants for the three and nine months ended September 30, 2016 have not been included in the loss per share calculation as the effects are anti-dilutive. Common stock equivalents comprising shares underlying 12,425,800 options and warrants for the three and nine months ended September 30, 2015 have not been included in the loss per share calculations as the effects are anti-dilutive. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Recent Accounting Pronouncements <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of adoption of ASU 2016-15. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, “Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting,” which relates to the accounting for employee share-based payments. This standard addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification flows of awards as either equity or liabilities; and (c) classification on the statement of cash flows. This standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is in the process of evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement on its consolidated financial statements. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In May 2014, the Financial Accounting Standards Board ("FASB") issued accounting guidance, "Revenue from Contracts with Customers." The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal year 2018. The Company is currently evaluating the impact this guidance will have on the consolidated financial statements. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-11, “Simplifying the Measurement of Inventory.” ASU 2015-11 applies to inventory that is measured using first-in, first-out (FIFO) or average cost. An entity should measure inventory within the scope of ASU 2015-11 at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016. The Company is in the process of evaluating the impact of this ASU on its consolidated financial statements. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In August 2014, the FASB issued ASU 2014-15, "Presentation of Financial Statements-Going Concern". This ASU is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. It is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The Company does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Fair Value of Financial Instruments <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The carrying value of the Company’s financial instruments, including cash, trade accounts receivable and accounts payable and accrued expenses and the face amount of notes payable approximate fair value for all periods. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Noncontrolling Interests <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest’s share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Concentration of Credit Risk <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">One customer in the nutraceutical and cosmetic additives division accounted for 13% and 81% of consolidated sales for each of the three month periods ended September 30, 2016 and 2015, respectively. This customer accounted for 15% and 83% of consolidated sales for the nine month periods ended September 30, 2016 and 2015, respectively. This customer accounted for 0% and 43% of accounts receivable at September 30, 2016 and December 31, 2015, respectively. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">A second customer in the nutraceutical and cosmetic additives division accounted for 3% and 13% of consolidated sales for each of the three month periods ended September 30, 2016 and 2015, respectively. This customer accounted for 2% and 13% of consolidated sales for the nine month periods ended September 30, 2016 and 2015, respectively. This customer accounted for 0% and 24% of accounts receivable at September 30, 2016 and December 31, 2015, respectively.

<table style="font: 10pt/normal times new roman, times, serif; width: 100%; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal times new roman, times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/normal times new roman, times, serif; width: 0.5in; text-align: justify; font-size-adjust: none; font-stretch: normal;">5.</td><td style="font: 10pt/normal times new roman, times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;">Stockholders’ Equity</td></tr></table> On April 1, 2016, the Company entered into two agreements with two consultants to provide services over a nine month period in exchange for 2,300,000 shares of common stock. The Company calculated a fair value of $690,000 based on the market price of the shares on the date of the agreements. During the third quarter of 2016, the Company and the consultants renegotiated the agreements by extending the service requirement to December 31, 2017. For the three and nine months ended September 30, 2016, the Company has recognized expense of $76,667 and $306,667, respectively, in connection with these agreements. On September 1, 2016, the Company issued 200,000 shares of common stock for $46,000. In connection with this issuance the Company issued 100,000 warrants with an exercise price of $0.50 per share. These warrants are fully vested and expire in two years. In August 2016, the Company issued 125,000 shares of common stock pursuant to sale of two promissory notes in the Offering. In September 2016, the Company issued 62,500 shares of common stock pursuant to the sale of one promissory note in the Offering. In the third quarter of 2016, the Company purchased 19,363 shares of outstanding Company common stock through an exchange for a price per share of $0.23 to $0.26. As of the September 30, 2016, these shares being held by the Company valued at cost is $4,720 and are included in treasury stock in the consolidated balance sheet. Service-Based Stock Options In May 2016, the Company issued 175,000 service-based options valued at $40,829 to two consultants at exercise prices of $0.20 per share. The options are fully vested and expire in 10 years. In July 2016, the Company issued 50,000 service-based options valued at $12,398 to a consultant with an exercise price of $0.20 per share. The options are fully vested and expire in 10 years. Accordingly, stock based compensation for the three and nine months ended September 30, 2016 included $12,398 and $53,227, respectively, related to such options. A Summary of the outstanding service-based options are as follows: <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;"> </td><td> </td><td style="padding-bottom: 1.5pt;"> </td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of Options</td><td style="padding-bottom: 1.5pt;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;"> </td><td>Balance at December 31, 2015</td><td style="width: 1%;"> </td><td style="width: 1%; text-align: left;"> </td><td style="width: 9%; text-align: right;">11,025,273</td><td style="width: 1%; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;"> </td><td>Cancelled</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">(250,000</td><td style="text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;"> </td><td style="padding-bottom: 1.5pt;">Issued</td><td style="padding-bottom: 1.5pt;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">225,000</td><td style="text-align: left; padding-bottom: 1.5pt;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;"> </td><td> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;"> </td><td style="padding-bottom: 4pt;">Balance at September 30, 2016</td><td style="padding-bottom: 4pt;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">11,000,273</td><td style="text-align: left; padding-bottom: 4pt;"> </td></tr></table> All outstanding options are exercisable and have a cashless exercise provision, and certain options provide for accelerated vesting provisions and modifications, as defined, if the Company is sold or acquired. The intrinsic value of options outstanding and exercisable at September 30, 2016 amounted to $750,294.  The significant assumptions used to determine the fair values of options issued, using a Black-Scholes option-pricing model are as follows: <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;"> </td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Significant assumptions :</td><td style="padding-bottom: 1.5pt;"> </td><td nowrap="nowrap" colspan="2"> </td><td style="padding-bottom: 1.5pt;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;"> </td><td style="text-align: left;">Risk-free interest rate at grant date</td><td> </td><td nowrap="nowrap" style="text-align: left;"> </td><td nowrap="nowrap" style="text-align: right;">0.78% - 1.88</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;"> </td><td style="text-align: left;">Expected stock price volatility</td><td> </td><td nowrap="nowrap" style="text-align: left;"> </td><td nowrap="nowrap" style="text-align: right;">222.9% - 248.4</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;"> </td><td style="text-align: left;">Expected dividend payout</td><td> </td><td nowrap="nowrap" style="text-align: left;"> </td><td nowrap="nowrap" style="text-align: right;">—</td><td style="text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;"> </td><td style="text-align: left;">Expected option life-years</td><td> </td><td nowrap="nowrap" style="text-align: left;"> </td><td nowrap="nowrap" style="text-align: right;">2 - 3</td><td style="text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;"> </td><td>Weighted average grant date fair value</td><td> </td><td nowrap="nowrap" style="text-align: left;">$</td><td nowrap="nowrap" style="text-align: right;">0.22 - 0.26</td><td style="text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 0.5in; background-color: white;"> </td><td style="text-align: left;">Forfeiture rate</td><td style="width: 1%;"> </td><td nowrap="nowrap" style="width: 1%; text-align: left;"> </td><td nowrap="nowrap" style="width: 9%; text-align: right;">0</td><td style="width: 1%; text-align: left;">%</td></tr></table> The following is a summary of outstanding service-based options at September 30, 2016: <table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Exercise Price</td><td style="padding-bottom: 1.5pt;"> </td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of Options</td><td style="padding-bottom: 1.5pt;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt;"> </td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: right;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;"> </td><td style="text-align: left;">$0.10</td><td style="width: 1%;"> </td><td style="width: 1%; text-align: left;"> </td><td style="width: 9%; text-align: right;">1,680,273</td><td style="width: 1%; text-align: left;"> </td><td style="width: 1%;"> </td><td style="width: 1%; text-align: center;"> </td><td style="width: 9%; text-align: center;">2 years</td><td style="width: 1%; text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;"> </td><td style="text-align: left;">$0.20 - $0.25</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">8,170,000</td><td style="text-align: left;"> </td><td> </td><td style="text-align: center;"> </td><td style="text-align: center;">6 years</td><td style="text-align: left;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;"> </td><td style="text-align: left; padding-bottom: 1.5pt;">$0.40</td><td style="padding-bottom: 1.5pt;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">1,150,000</td><td style="text-align: left; padding-bottom: 1.5pt;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="text-align: center; padding-bottom: 1.5pt;"> </td><td style="text-align: center; padding-bottom: 1.5pt;">5 years</td><td style="text-align: left; padding-bottom: 1.5pt;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;"> </td><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total</td><td style="padding-bottom: 4pt;"> </td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"> </td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">11,000,273</td><td style="text-align: left; padding-bottom: 4pt;"> </td><td style="padding-bottom: 4pt;"> </td><td style="text-align: center; padding-bottom: 4pt;"> </td><td style="text-align: center; padding-bottom: 4pt;"> </td><td style="text-align: left; padding-bottom: 4pt;"> </td></tr></table> Performance-Based Stock Options The Company had granted performance-based options to purchase 4,400,000 shares of common stock at exercise prices of $0.40 to $0.80. The options expire at various dates between 2021 and 2026 and are exercisable upon the Company achieving annual sales revenue of $5,000,000 and $10,000,000. The fair value of these performance-based options aggregated $169,035 to be expensed over the implicit service period commencing once management believes the performance criteria will be met. Management believes the performance criteria for options exercisable upon the Company achieving annual sales revenue of $5,000,000, with a fair value amounting to $133,324, will be met during the year ended December 31, 2016. Accordingly, stock based compensation expense for the three and nine months ended September 30, 2016 includes $55,591 and $133,324, respectively, related to such options. At September 30, 2016, the unearned compensation for all the performance based options is $35,711. Stock based compensation expense amounted to $165,241 and $10,500 for the three month periods ended September 30, 2016 and 2015, respectively. Stock based compensation expense amounted to $513,804 and $14,500 for the nine month periods ended September 30, 2016 and 2015, respectively. Such amounts are included in compensation and related expenses in the accompanying statement of operations. Warrants In September 2016, the Company issued 100,000 warrants with an exercise price of $0.50 per share, in relation to a sale of common stock. These warrants are fully vested and expire in two years. In September 2016, the Company issued 100,000 warrants with exercise prices between $0.20 and $0.50 per share, for consulting services. These warrants are fully vested and expire in three years. The fair value of these warrants are $20,585 and is included in compensation and related expenses in the accompanying statement of operations. Warrants outstanding and exercisable amounted to 1,950,000 and 1,750,000 at September 30, 2016 and December 31, 2015, respectively. The weighted average exercise price of warrants outstanding at September 30, 2016 is $0.19. The warrants expire during November 2016 and September 2019.

<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Unaudited Financial Statements<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for financial information and with the instructions to Form 10-Q. They do not include all information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The unaudited financial statements should be read in conjunction with those financial statements included in the Company’s previously filed Form 10-K for the year ended December 31, 2015. In the opinion of management, all adjustments considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Basis of Presentation and Use of Estimates<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The consolidated financial statements include the accounts of the Company and its controlled subsidiary, Immudyne PR. The non- controlling interest in Immudyne PR represents the 21.833% equity interest held by other members of the joint venture. All intercompany transactions have been eliminated.<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the valuation of inventory and stockholders’ equity based transactions. Actual results could differ from those estimates.

<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Inventory<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">At September 30, 2016 and December 31, 2015, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic products. Inventory is maintained in the Company’s leased Kentucky warehouse and third party warehouses in Pennsylvania and Louisiana.<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 36pt; margin: 0pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Inventory is valued at the lower of cost or market with cost determined on a first-in, first-out (“FIFO”) basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to market value, if lower. At September 30, 2016 and December 31, 2015, the Company recorded an inventory reserve in the amount of $20,000. Inventory consists of the following:<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 36pt; margin: 0pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> <table style="widows: 1; text-transform: none; text-indent: 0px; width: 1567px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;"> </td><td> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">September 30, 2016</td><td style="padding-bottom: 1.5pt;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">December 31, 2015</td><td style="padding-bottom: 1.5pt;"> </td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;"> </td><td> </td><td> </td><td style="text-align: right;" colspan="2"> </td><td> </td><td> </td><td style="text-align: right;" colspan="2"> </td><td> </td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="background-color: white; width: 0.5in;"> </td><td style="text-align: left;">Raw materials</td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 141px;">49,083</td><td style="text-align: left; width: 15px;"> </td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 141px;">25,761</td><td style="text-align: left; width: 15px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="background-color: white;"> </td><td style="text-align: left; padding-bottom: 1.5pt;">Finished products</td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom: black 1.5pt solid; text-align: left;"> </td><td style="border-bottom: black 1.5pt solid; text-align: right;">81,447</td><td style="text-align: left; padding-bottom: 1.5pt;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom: black 1.5pt solid; text-align: left;"> </td><td style="border-bottom: black 1.5pt solid; text-align: right;">35,290</td><td style="text-align: left; padding-bottom: 1.5pt;"> </td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="background-color: white;"> </td><td style="padding-bottom: 4pt;"> </td><td style="padding-bottom: 4pt;"> </td><td style="border-bottom: black 4pt double; text-align: left;">$</td><td style="border-bottom: black 4pt double; text-align: right;">130,530</td><td style="text-align: left; padding-bottom: 4pt;"> </td><td style="padding-bottom: 4pt;"> </td><td style="border-bottom: black 4pt double; text-align: left;">$</td><td style="border-bottom: black 4pt double; text-align: right;">61,051</td></tr></table>

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Segments <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The guidance for disclosures about segments of an enterprise requires that a public business enterprise report financial and descriptive information about its operating segments. Generally, financial information is required to be reported on the basis used internally for evaluating segment performance and resource allocation. The Company manages its operations in two reportable segments for purposes of assessing performance and making operating decisions. Revenue is generated predominately in the United States, and all significant assets are held in the United States, or United States territories. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">A summary of the company’s reportable segments is as follows: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold;">Total assets:</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold;"> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December 31, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 0.5in; background-color: white;"> </td> <td style="text-align: left;">Nutraceutical and Cosmetic Additives</td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">519,646</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">412,324</td> <td style="width: 15px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Finished Cosmetic Products</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">695,205</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">101,828</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Eliminations</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(135,476</td> <td style="text-align: left; padding-bottom: 1.5pt;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(65,681</td> <td style="text-align: left; padding-bottom: 1.5pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;">Total</td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,079,375</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">448,471</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold;">Total sales:</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold;"> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Three months ended</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Nine months ended</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 0.5in; background-color: white;"> </td> <td style="text-align: left;">Nutraceutical and Cosmetic Additives</td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">229,741</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">279,883</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">780,961</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">845,513</td> <td style="width: 15px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Finished Cosmetic Products</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,154,688</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,494,743</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Eliminations</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(23,000</td> <td style="text-align: left; padding-bottom: 1.5pt;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;">Total</td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,384,429</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">279,883</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">4,252,704</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">845,513</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Net (loss) income:</td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-size: 10pt;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">Three months ended</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">Nine months ended</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-size: 10pt;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">September 30, 2016</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">September 30, 2015</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">September 30, 2016</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">September 30, 2015</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 0.5in; background-color: white;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Nutraceutical and Cosmetic Additives</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">(258,713</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">)</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">8,119</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">(653,757</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">)</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">(11,243</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Finished Cosmetic Products</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">41,017</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">171,520</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">Eliminations</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">Total</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(217,696</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">)</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">8,119</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(482,237</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">)</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(11,243</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">)</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">   <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">As of and for the nine months ended September 30, 2015, there were no assets, sales or net loss relative to the finished cosmetic products segment.

Recent Accounting Pronouncements In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of adoption of ASU 2016-15. In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, “Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting,” which relates to the accounting for employee share-based payments. This standard addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification flows of awards as either equity or liabilities; and (c) classification on the statement of cash flows. This standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is in the process of evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements. In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement on its consolidated financial statements. In May 2014, the Financial Accounting Standards Board ("FASB") issued accounting guidance, "Revenue from Contracts with Customers." The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal year 2018. The Company is currently evaluating the impact this guidance will have on the consolidated financial statements. In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-11, “Simplifying the Measurement of Inventory.” ASU 2015-11 applies to inventory that is measured using first-in, first-out (FIFO) or average cost. An entity should measure inventory within the scope of ASU 2015-11 at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016. The Company is in the process of evaluating the impact of this ASU on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, "Presentation of Financial Statements-Going Concern". This ASU is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. It is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The Company does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows. All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.

<p style="widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Noncontrolling Interests<p style="widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest’s share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.

<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Concentration of Credit Risk<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">One customer in the nutraceutical and cosmetic additives division accounted for 13% and 81% of consolidated sales for each of the three month periods ended September 30, 2016 and 2015, respectively. This customer accounted for 15% and 83% of consolidated sales for the nine month periods ended September 30, 2016 and 2015, respectively. This customer accounted for 0% and 43% of accounts receivable at September 30, 2016 and December 31, 2015, respectively.<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">A second customer in the nutraceutical and cosmetic additives division accounted for 3% and 13% of consolidated sales for each of the three month periods ended September 30, 2016 and 2015, respectively. This customer accounted for 2% and 13% of consolidated sales for the nine month periods ended September 30, 2016 and 2015, respectively. This customer accounted for 0% and 24% of accounts receivable at September 30, 2016 and December 31, 2015, respectively.

<table style="widows: 1; text-transform: none; text-indent: 0px; width: 1567px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;"> </td><td> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">September 30, 2016</td><td style="padding-bottom: 1.5pt;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">December 31, 2015</td><td style="padding-bottom: 1.5pt;"> </td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;"> </td><td> </td><td> </td><td style="text-align: right;" colspan="2"> </td><td> </td><td> </td><td style="text-align: right;" colspan="2"> </td><td> </td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="background-color: white; width: 0.5in;"> </td><td style="text-align: left;">Raw materials</td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 141px;">49,083</td><td style="text-align: left; width: 15px;"> </td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 141px;">25,761</td><td style="text-align: left; width: 15px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="background-color: white;"> </td><td style="text-align: left; padding-bottom: 1.5pt;">Finished products</td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom: black 1.5pt solid; text-align: left;"> </td><td style="border-bottom: black 1.5pt solid; text-align: right;">81,447</td><td style="text-align: left; padding-bottom: 1.5pt;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom: black 1.5pt solid; text-align: left;"> </td><td style="border-bottom: black 1.5pt solid; text-align: right;">35,290</td><td style="text-align: left; padding-bottom: 1.5pt;"> </td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="background-color: white;"> </td><td style="padding-bottom: 4pt;"> </td><td style="padding-bottom: 4pt;"> </td><td style="border-bottom: black 4pt double; text-align: left;">$</td><td style="border-bottom: black 4pt double; text-align: right;">130,530</td><td style="text-align: left; padding-bottom: 4pt;"> </td><td style="padding-bottom: 4pt;"> </td><td style="border-bottom: black 4pt double; text-align: left;">$</td><td style="border-bottom: black 4pt double; text-align: right;">61,051</td></tr></table>

<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold;">Total assets:</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold;"> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December 31, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 0.5in; background-color: white;"> </td> <td style="text-align: left;">Nutraceutical and Cosmetic Additives</td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">519,646</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">412,324</td> <td style="width: 15px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Finished Cosmetic Products</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">695,205</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">101,828</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Eliminations</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(135,476</td> <td style="text-align: left; padding-bottom: 1.5pt;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(65,681</td> <td style="text-align: left; padding-bottom: 1.5pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;">Total</td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,079,375</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">448,471</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold;">Total sales:</td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-weight: bold;"> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Three months ended</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Nine months ended</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2016</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2015</td> <td style="padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 0.5in; background-color: white;"> </td> <td style="text-align: left;">Nutraceutical and Cosmetic Additives</td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">229,741</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">279,883</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">780,961</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">845,513</td> <td style="width: 15px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="text-align: left;">Finished Cosmetic Products</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,154,688</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,494,743</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 1.5pt;">Eliminations</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(23,000</td> <td style="text-align: left; padding-bottom: 1.5pt;">)</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 1.5pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;">Total</td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,384,429</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">279,883</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">4,252,704</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> <td style="padding-bottom: 4pt; font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td> <td style="text-align: right; font-weight: bold; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">845,513</td> <td style="text-align: left; padding-bottom: 4pt; font-weight: bold;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Net (loss) income:</td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-size: 10pt;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">Three months ended</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">Nine months ended</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="background-color: white;"> </td> <td style="font-size: 10pt;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">September 30, 2016</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">September 30, 2015</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">September 30, 2016</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">September 30, 2015</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="width: 0.5in; background-color: white;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Nutraceutical and Cosmetic Additives</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">(258,713</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">)</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">8,119</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">(653,757</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">)</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">(11,243</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Finished Cosmetic Products</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">41,017</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">171,520</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="background-color: white;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">Eliminations</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="background-color: white;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">Total</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(217,696</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">)</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">8,119</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(482,237</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">)</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(11,243</td> <td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">)</td> </tr> </table>

<table style="width: 1567px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; font-stretch: normal;" cellspacing="0" cellpadding="0"><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="background-color: white; width: 0.5in;"> </td><td style="text-align: left;">Deferred Tax Asset</td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 141px;">930,000</td><td style="text-align: left; width: 15px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="background-color: white;"> </td><td style="text-align: left; padding-bottom: 1.5pt;">Valuation allowance</td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom: black 1.5pt solid; text-align: left;"> </td><td style="border-bottom: black 1.5pt solid; text-align: right;">(930,000</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="widows: 1; text-transform: none; background-color: white; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"> </td><td style="padding-bottom: 4pt; widows: 1; text-transform: none; text-indent: 0px; padding-left: 10pt; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Total</td><td style="padding-bottom: 4pt; widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"> </td><td style="border-bottom: black 4pt double; text-align: left; widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">$</td><td style="border-bottom: black 4pt double; text-align: right; widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">-</td></tr></table>

<table style="widows: 1; text-transform: none; text-indent: 0px; width: 1567px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;"></td><td style="border-bottom: black 1.5pt solid;">Significant assumptions :</td><td style="padding-bottom: 1.5pt;"> </td><td colspan="2" nowrap="nowrap"> </td><td style="padding-bottom: 1.5pt;"> </td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="background-color: white;"> </td><td style="text-align: left;">Risk-free interest rate at grant date</td><td> </td><td style="text-align: left;" nowrap="nowrap"> </td><td style="text-align: right;" nowrap="nowrap">0.78% - 1.88</td><td style="text-align: left;">%</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="background-color: white;"> </td><td style="text-align: left;">Expected stock price volatility</td><td> </td><td style="text-align: left;" nowrap="nowrap"> </td><td style="text-align: right;" nowrap="nowrap">222.9% - 248.4</td><td style="text-align: left;">%</td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="background-color: white;"> </td><td style="text-align: left;">Expected dividend payout</td><td> </td><td style="text-align: left;" nowrap="nowrap"> </td><td style="text-align: right;" nowrap="nowrap">—</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="background-color: white;"> </td><td style="text-align: left;">Expected option life-years</td><td> </td><td style="text-align: left;" nowrap="nowrap"> </td><td style="text-align: right;" nowrap="nowrap">2 - 3</td><td style="text-align: left;"> </td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="background-color: white;"> </td><td>Weighted average grant date fair value</td><td> </td><td style="text-align: left;" nowrap="nowrap">$</td><td style="text-align: right;" nowrap="nowrap">0.22 - 0.26</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="background-color: white; width: 0.5in;"> </td><td style="text-align: left;">Forfeiture rate</td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;" nowrap="nowrap"> </td><td style="text-align: right; width: 141px;" nowrap="nowrap">0</td><td style="text-align: left; width: 15px;">%</td></tr></table>

<table style="widows: 1; text-transform: none; text-indent: 0px; width: 1567px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;"> </td><td style="border-bottom: black 1.5pt solid; text-align: left;">Exercise Price</td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">Number of Options</td><td style="padding-bottom: 1.5pt;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom: black 1.5pt solid; text-align: center;" colspan="2">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1.5pt;"> </td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: right;" colspan="2"> </td><td> </td><td> </td><td style="text-align: center;" colspan="2"> </td><td> </td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="background-color: white; width: 0.5in;"> </td><td style="text-align: left;">$0.10</td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;"> </td><td style="text-align: right; width: 141px;">1,680,273</td><td style="text-align: left; width: 15px;"> </td><td style="width: 15px;"> </td><td style="text-align: center; width: 15px;"> </td><td style="text-align: center; width: 141px;">2 years</td><td style="text-align: left; width: 15px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="background-color: white;"> </td><td style="text-align: left;">$0.20 - $0.25</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">8,170,000</td><td style="text-align: left;"> </td><td> </td><td style="text-align: center;"> </td><td style="text-align: center;">6 years</td><td style="text-align: left;"> </td></tr><tr style="background-color: #cceeff; vertical-align: bottom;"><td style="background-color: white;"> </td><td style="text-align: left; padding-bottom: 1.5pt;">$0.40</td><td style="padding-bottom: 1.5pt;"> </td><td style="border-bottom: black 1.5pt solid; text-align: left;"> </td><td style="border-bottom: black 1.5pt solid; text-align: right;">1,150,000</td><td style="text-align: left; padding-bottom: 1.5pt;"> </td><td style="padding-bottom: 1.5pt;"> </td><td style="text-align: center; padding-bottom: 1.5pt;"> </td><td style="text-align: center; padding-bottom: 1.5pt;">5 years</td><td style="text-align: left; padding-bottom: 1.5pt;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="background-color: white;"> </td><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total</td><td style="padding-bottom: 4pt;"> </td><td style="border-bottom: black 4pt double; text-align: left;"> </td><td style="border-bottom: black 4pt double; text-align: right;">11,000,273</td><td style="text-align: left; padding-bottom: 4pt;"> </td><td style="padding-bottom: 4pt;"> </td><td style="text-align: center; padding-bottom: 4pt;"> </td><td style="text-align: center; padding-bottom: 4pt;"> </td><td style="text-align: left; padding-bottom: 4pt;"> </td></tr></table>

0.3333

0.7816667

0.51

25761

49083

35290

81447

448471

412324

101828

-65681

1079375

519646

695205

-135476

0.81 0.13 0.13 0.03 0.21833

20000

530000

1578000

12425800

12950273

0.81

0.13

0.83

0.13

0.43

0.24

0.13

0.03

0.15

0.02

0.00

18000

122000

100000

0.11

5175

9247

14422

23517

9531

33048

2750

9992

8250

313

15805

2016-11-01

0.11

P6M

50000

18800

In August and September 2016, the Company sold promissory notes totaling $150,000 to three unrelated individuals. Two of the promissory notes totaling $100,000 are payable in February 2017 and one promissory note for $50,000 is payable in March 2017.

150000

930000

2730000

2035-12-31

0.34

11025273

11000273

1680273

8120000

1150000

250000

175000

50000

4400000

225000

0.0188

0.0078

2.484

2.229

P3Y

P2Y

0.26

0.22

0.00

0.10

0.40

0.20

0.25

P2Y

P6Y

P5Y

10500

14500

76667

165241

306667

513804

750294

40829 12398

P10Y

P2Y

2017-12-31

2021-12-31

2026-12-31

0.20

0.40

0.80

5000000 10000000

133324

35711

1750000

1950000

1750000 1950000

0.50

0.19

0.20

0.50

Warrants expire during November 2016 and September 2019. 169035 2 1

100000

19363

Company common stock through an exchange for a price per share of $0.23 to $0.26. 227175 0.08

20157

0.60

56579

84868

0.17

2016-05-31

9000

15286

50350

27706

71606

145000

0.40

0.80

4400000 0.15

<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Company has entered into two agreements on April 1, 2016 with two consultants of Immudyne PR for business development, marketing and sales related services (the “Consultant Agreements”). Upon signing, each consultant was issued 1,000,000 restricted shares of Immudyne, Inc. common stock. In addition, each consultant shall receive an additional 150,000 restricted shares of Immudyne, Inc. common stock for each $500,000 distributed by Immudyne PR to the Company. For each consultant the amount of shares to be issued by the Company to the consultants shall be capped at 1,500,000 restricted shares when Immudyne PR has transferred $5,000,000 to the Company, for a combined capped total of 3,000,000 restricted shares. For the three and nine months ended September 30, 2016, 2,300,000 restricted shares of common stock have been issued related to these agreements.<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">   <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0pt 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In addition, the Consulting Agreements provided that each consultant shall receive a bonus of an additional 750,000 restricted shares of Immudyne Inc. common stock, plus an option to buy 1,000,000 shares of Immudyne, Inc. common stock at $0.20/share (including a cashless exercise feature) when Immudyne PR has transferred to the Company at each of the following three (3) thresholds: $1,250,000, $2,000,000 and $3,000,000 for a total of 2,250,000 of restricted shares of Immudyne, Inc. common stock and options to purchase up to 3,000,000 shares of Immudyne, Inc. common stock at $0.20/share. As of September 30, 2016, no bonus shares have been issued and no options have been granted under this agreement.

1000000

2300000

1000000 750000

0.30

6000 15000 6000 20000

100000

50000

62500

EX-101.SCH 5 immd-20160930.xsd XBRL SCHEMA FILE 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Consolidated Statement of Stockholders' Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization and Going Concern link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Notes Payable link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Royalties link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Organization and Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Summary of Significant Accounting Policies (Details 1) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Stockholders' Equity (Details 1) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Stockholders' Equity (Details 2) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Royalties (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 immd-20160930_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 immd-20160930_def.xml XBRL DEFINITION FILE EX-101.LAB 8 immd-20160930_lab.xml XBRL LABEL FILE Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Amendment Flag Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Filer Category Entity Common Stock, Shares Outstanding Statement of Financial Position [Abstract] Assets [Abstract] ASSETS Assets, Current [Abstract] Current Assets Cash and Cash Equivalents, at Carrying Value Cash Cash at beginning of the period Cash at end of the period Accounts Receivable, Net, Current, Total Trade accounts receivable, net Inventory, Net, Total Inventory, net Inventory, net Inventory, net Assets, Current, Total Total Current Assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities, Current [Abstract] Current Liabilities Accounts Payable and Accrued Liabilities, Current, Total Accounts payable and accrued expenses Notes Payable, Current Notes payable, net of discount Beginning Balance Ending Balance Liabilities, Current, Total Total Current Liabilities Stockholders' Equity Attributable to Parent [Abstract] Immudyne, Inc. Stockholders' equity Stockholders' equity Common Stock, Value, Issued Common stock, $0.01 par value; 50,000,000 shares authorized, 34,697,875 and 32,010,375 shares issued, 34,678,512 and 32,010,375 outstanding as of September 30, 2016 and December 31, 2015, respectively Common stock, $0.01 par value; 50,000,000 shares authorized, 30,609,973 shares issued and outstanding at June 30, 2015 Common stock issued, value Additional Paid in Capital, Total Additional paid-in capital Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit) Accumulated (deficit) Accumulated deficit Accumulated (deficit) Equity Equity It represents total of common stock, additional paid in capital and accumulated deficit. Treasury Stock, Value Treasury stock Treasury stock,19,363 shares, at cost Stockholders' Equity Attributable to Parent Total Immudyne, Inc. Stockholders' Equity Balance Balance Stockholders' Equity Attributable to Noncontrolling Interest Non-controlling interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total Stockholders' Equity Balance Balance Liabilities and Equity Total Liabilities and Stockholders' Equity Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Treasury Stock, Common, Shares Treasury stock, common, shares Income Statement [Abstract] Revenues, Total Total sales Net sales Revenue Cost of Revenue, Total Cost of sales Gross Profit, Total Gross Profit Operating Expenses [Abstract] Operating expenses Compensation and Related Expenses Compensation and related expenses Represents the expense recognized during the period arising from equity-based compensation arrangements and related expenses (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees. Compensation and related expenses Professional Fees Professional fees Consulting expense Professional fees General and Administrative Expense, Total General and administrative expenses General and administrative expenses Operating Expenses Total operating expenses Operating Income (Loss), Total Operating Income (Loss) Operating income (Loss) Interest Expense Interest expense Interest (expense) Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest, Total Net Income (Loss) Before Taxes Deferred Income Tax Expense (Benefit) Deferred tax benefit Deferred income tax benefit Deferred income tax benefit Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net (loss) Net (Loss) Net Income (Loss) Net (loss) income Net Income (Loss) Attributable to Noncontrolling Interest Net income (loss) attributable to noncontrolling interests Net (loss) attributable to noncontrolling interests Net Income (Loss) Attributable to Parent Net (loss) Net (Loss) Net income (loss) attributable to Immudyne, Inc. Net (loss) income Earnings Per Share, Basic and Diluted Basic and diluted (loss) per share attributable to Immudyne, Inc. Earnings Per Share [Abstract] Average number of common shares outstanding Earnings Per Share, Basic Basic Earnings Per Share, Diluted Diluted Statement of Stockholders' Equity [Abstract] Statement [Table] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Accumulated (Deficit) [Member] Accumulated (Deficit) Treasury Stock [Member] Treasury Stock Summation [Member] Sub Total Sub total Member. Noncontrolling Interest [Member] Noncontrolling interest Statement [Line Items] Shares, Outstanding Balance, (in shares) Balance (in shares) Adjustments Of Addition Paid In Capital Amortization Of Stock Options Amortization of stock options Amount of decrease in additional paid in capital (APIC) resulting from amortization of stock options. Stock Issued During Period, Value, Issued for Services Common stock issued for services as per agreement Issuance of common stock for services Stock Issued During Period, Shares, Issued for Services Common stock issued for services as per agreement, shares Issuance of common stock for services, shares Stock Issued During Period, Value, New Issues Sale of common stock and warrants Issuance of company stock, value Stock Issued During Period, Shares, New Issues Purchase of Company stock, shares Issuance of Company stock, shares Sale of common stock and warrants, shares Common stock shares issued Purchase of Company stock, shares Stock Issued During Period, Value, Conversion of Convertible Securities Issuance of common stock in relation to debt offering Issuance of common stock in relation to debt offering Issue of common stock, value Issuance of common stock in relation to debt offering Stock Issued During Period, Shares, Conversion of Convertible Securities Issue of common stock Issuance of common stock in relation to debt offering, shares Adjustment of Warrants Granted for Services Issuance of warrants for services Noncontrolling Interest, Period Increase (Decrease) Reduction in noncontrolling interest Treasury Stock, Value, Acquired, Cost Method Purchase of treasury stock Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Issuance of stock options Noncontrolling Interest, Increase from Subsidiary Equity Issuance Investment in subsidiary by noncontrolling interest Statement Of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net (loss) to net cash (used) provided by operating activities Adjustments to reconcile net (loss) to net cash (used) by operating activities Depreciation Depreciation Depreciation Depreciation expense Provision for Doubtful Accounts Bad debt provision Amortization of Debt Discount (Premium) Amortization of debt discount Share-based Compensation Stock based compensation Stock compensation expense Increase (Decrease) In Operating Capital [Abstract] Changes in Assets And Liabilities Increase (Decrease) In Accounts Receivable Trade accounts receivable Increase (Decrease) in Inventories, Total Inventory Increase (Decrease) In Other Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Net Cash Provided by (Used in) Operating Activities, Total Negative cash flows from operations Net cash (used) by operating activities Net Cash Provided By (Used In) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from (Payments to) Noncontrolling Interests Investment in subsidiary by noncontrolling interest Increase in notes payable Increase in notes payable Repayments of Notes Payable Repayment of note payable Repayment Repayment of notes payable Issuance Of Common Stock And Warrants Sale of common stock and warrants Issuance of common stock and warrants. Proceeds from Issuance of Common Stock Purchase of treasury stock Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease), Total Net increase (decrease) in cash Supplemental Cash Flow Information [Abstract] Supplemental Disclosure of Cash Flow Information Supplemental Cash Flow Information [Abstract] Interest Paid Cash paid during the period for interest Conversion of Stock, Amount Issued Issuance of common stock for notes payable Issuance Of Common Stock In Relation To Debt Offering Issuance of common stock in relation to debt offering Issuance of common stock in relation to debt offering. Issuance of Stock and Warrants for Services or Claims Issuance of common stock for services Issuance of warrants for services Issuance of warrants for services Organization and Going Concern [Abstract] Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block] Organization and Going Concern Organization and Going Concern Summary of Significant Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Notes Payable [Abstract] Debt Disclosure [Text Block] Notes Payable Income Taxes [Abstract] Income Taxes [Abstract] Income Tax Disclosure [Text Block] Income Taxes Stockholders' Equity [Abstract] Stockholders Equity Note Disclosure [Text Block] Stockholders' Equity Royalties [Abstract] Royalties Disclosure [Text Block] Royalties The entire disclosure for royalty agreement during the reporting period. Commitments and Contingencies [Abstract] Commitments and Contingencies [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Related Party Transactions Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events Unaudited Interim Financial Statements [Policy Text Block] Unaudited Financial Statements Disclosure of accounting policy pertaining to unaudited interim financial statements. Basis Of Presentation and Use Of Estimates Policy [Policy Text Block] Basis of Presentation and Use of Estimates Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements and use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. Inventory, Policy [Policy Text Block] Inventory Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Trade and Other Accounts Receivable, Policy [Policy Text Block] Accounts receivable Segment Reporting, Policy [Policy Text Block] Segments Income Tax, Policy [Policy Text Block] Income Taxes Compensation Related Costs, Policy [Policy Text Block] Stock-Based Compensation Earnings Per Share, Policy [Policy Text Block] Earnings (Loss) Per Share New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Fair Value Of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Minority Interest [Policy Text Block] Noncontrolling Interests Disclosure of noncontrolling interests policy for credit risk. Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Schedule Of Inventory, Current [Table Text Block] Summary of inventory Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] Summary of reportable segments Schedule Of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of deferred tax asset Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Equity Award [Domain] Employee Stock Option [Member] Stock Options [Member] Option [Member] Service-Based Stock Options [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of outstanding service-based options Schedule of Assumptions Used [Table Text Block] Summary of significant assumptions used to determine fair values of options issued using Black-Scholes option-pricing model Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Summary of outstanding service-based options exercise price Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Domain] Immudyne Pr Llc [Member] Immudyne PR LLC [Member] Immudyne PR LLC. Related Party Transaction [Line Items] Organization And Going Concern Textual [Abstract] Organization and Going Concern (Textual) organization and going concern textual. Equity Method Investment, Ownership Percentage Percentage of ownership of equity interest Noncontrolling Interest, Ownership Percentage by Parent Percentage of voting controlling interest Inventory, Net [Abstract] Summary of inventory Inventory, Raw Materials, Gross Raw materials Inventory, Finished Goods, Gross Finished products Schedule of Revenue by Major Customers, by Reporting Segments [Table] Consolidation Items [Axis] Consolidation Items [Domain] Nutraceutical And Cosmetic [Member] Nutraceutical and cosmetic [Member] Nutraceutical and cosmetic member. Cosmetic Goods [Member] Finished Cosmetic Products [Member] Cosmetic goods member. Intersegment Eliminations [Member] Elimination [Member] Revenue, Major Customer [Line Items] Summary of reportable segments [Line Items] Assets, Total Total assets Total Assets Option Indexed to Issuer's Equity [Table] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Domain] Warrant [Member] Warrant [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Sales [Member] Accounts Receivable [Member] Concentration Risk Number Of Customers [Axis] Concentration Risk Number Of Customers [Domain] One Customer [Member] Second Customer [Member] Option Indexed to Issuer's Equity [Line Items] Summary Of Significant Accounting Policies Textual [Abstract] Summary of Significant Accounting Policies (Textual) Summary of significant accounting policies textual. Minority Interest Rate Non controlling interest rate Non controlling stated interest rate. Inventory, LIFO Reserve Inventory reserve Sales Discounts, Returns and Allowances, Goods Customer discounts, returns and rebates Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share Concentration Risk, Percentage Concentration risk percentage Accounts Receivable, Net Accounts receivable reserve Schedule of Long-term Debt Instruments [Table] Title of Individual [Axis] Relationship to Entity [Domain] EX-101.PRE 9 immd-20160930_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Nov. 14, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Immudyne, Inc.
Entity Central Index Key	0000948320
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		34,760,375

XML 11 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current Assets
Cash	$ 473,921	$ 232,984
Trade accounts receivable, net	474,924	154,436
Inventory, net	130,530	61,051
Total Current Assets	1,079,375	448,471
Current Liabilities
Accounts payable and accrued expenses	408,194	167,481
Notes payable, net of discount	214,115	100,000
Total Current Liabilities	622,309	267,481
Immudyne, Inc. Stockholders' equity
Common stock, $0.01 par value; 50,000,000 shares authorized, 34,697,875 and 32,010,375 shares issued, 34,678,512 and 32,010,375 outstanding as of September 30, 2016 and December 31, 2015, respectively	346,978	320,103
Additional paid-in capital	9,032,728	8,366,313
Accumulated (deficit)	(9,075,014)	(8,586,338)
Equity	304,692	100,078
Treasury stock,19,363 shares, at cost	(4,720)
Total Immudyne, Inc. Stockholders' Equity	299,972	100,078
Non-controlling interest	157,094	80,912
Total Stockholders' Equity	457,066	180,990
Total Liabilities and Stockholders' Equity	$ 1,079,375	$ 448,471

XML 12 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	34,697,875	32,010,375
Common stock, shares outstanding	34,678,512	32,010,375
Treasury stock, common, shares	19,363

XML 13 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Net sales	$ 1,384,429	$ 279,883	$ 4,252,704	$ 845,513
Cost of sales	942,738	73,988	2,981,657	237,707
Gross Profit	441,691	205,895	1,271,047	607,806
Operating expenses
Compensation and related expenses	361,829	101,137	1,077,340	301,301
Professional fees	82,608	29,237	277,282	91,059
General and administrative expenses	204,958	57,580	382,857	206,841
Total operating expenses	649,395	187,954	1,737,479	599,201
Operating Income (Loss)	(207,704)	17,941	(466,432)	8,605
Interest (expense)	(9,992)	(14,422)	(15,805)	(33,048)
Net Income (Loss) Before Taxes	(217,696)	3,519	(482,237)	(24,443)
Deferred income tax benefit		4,600		13,200
Net Income (Loss)	(217,696)	8,119	(482,237)	(11,243)
Net income (loss) attributable to noncontrolling interests	8,955		6,439
Net income (loss) attributable to Immudyne, Inc.	$ (226,651)	$ 8,119	$ (488,676)	$ (11,243)
Basic and diluted (loss) per share attributable to Immudyne, Inc.	$ (0.01)	$ 0.00	$ (0.02)	$ (0.00)
Average number of common shares outstanding
Basic	34,427,087	30,650,000	31,917,873	30,663,306
Diluted	$ 34,427,087	$ 30,650,000	$ 31,917,873	$ 30,663,306

XML 14 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Stockholders' Equity (Unaudited) - 9 months ended Sep. 30, 2016 - USD ($)	Total	Common Stock	Additional Paid-in Capital	Accumulated (Deficit)	Treasury Stock	Sub Total	Noncontrolling interest
Balance at Dec. 31, 2015	$ 180,990	$ 320,103	$ 8,366,313	$ (8,586,338)		$ 100,078	$ 80,912
Balance, (in shares) at Dec. 31, 2015		32,010,375
Amortization of stock options	133,324		133,324			133,324
Issuance of common stock for services	306,667	$ 23,000	283,667			306,667
Issuance of common stock for services, shares		2,300,000
Sale of common stock and warrants	46,000	$ 2,000	44,000			46,000
Sale of common stock and warrants, shares		200,000
Issuance of common stock in relation to debt offering	41,875	$ 1,875	40,000			41,875
Issuance of common stock in relation to debt offering, shares		187,500
Issuance of warrants for services	20,585		20,585			20,585
Reduction in noncontrolling interest			91,612			91,612	(91,612)
Purchase of treasury stock	(4,720)				(4,720)	(4,720)
Issuance of stock options	53,227		53,227			53,227
Investment in subsidiary by noncontrolling interest	161,355						161,355
Net (loss)	(482,237)			(488,676)		(488,676)	6,439
Balance at Sep. 30, 2016	$ 457,066	$ 346,978	$ 9,032,728	$ (9,075,014)	$ (4,720)	$ 299,972	$ 157,094
Balance (in shares) at Sep. 30, 2016		34,697,875

XML 15 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss)	$ (482,237)	$ (11,243)
Adjustments to reconcile net (loss) to net cash (used) by operating activities
Depreciation		43,748
Bad debt provision	(43,558)
Amortization of debt discount	5,990
Deferred tax benefit		(13,200)
Stock compensation expense	493,218	14,500
Issuance of warrants for services	20,585
Changes in Assets And Liabilities
Trade accounts receivable	(276,930)	(116,754)
Inventory	(69,479)	1,579
Accounts payable and accrued expenses	240,713	1,059
Net cash (used) by operating activities	(111,698)	(80,311)
CASH FLOWS FROM FINANCING ACTIVITIES
Investment in subsidiary by noncontrolling interest	161,355
Increase in notes payable	150,000	205,000
Repayment of notes payable		(115,522)
Sale of common stock and warrants	46,000
Purchase of treasury stock	(4,720)	(10,800)
Net cash provided by financing activities	352,635	78,678
Net increase (decrease) in cash	240,937	(1,633)
Cash at beginning of the period	232,984	75,495
Cash at end of the period	473,921	73,862
Supplemental Disclosure of Cash Flow Information
Cash paid during the period for interest	8,563	24,547
Issuance of common stock for notes payable		10,200
Issuance of common stock in relation to debt offering	41,875
Issuance of common stock for services	$ 581,093

XML 16 R7.htm IDEA: XBRL DOCUMENT

Organization and Going Concern

9 Months Ended

Sep. 30, 2016

Organization and Going Concern [Abstract]

Organization and Going Concern

1.	Organization and Going Concern

XML 17 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2016

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Unaudited Financial Statements

Basis of Presentation and Use of Estimates

Inventory

	September 30, 2016		December 31, 2015

Raw materials	$	49,083	$	25,761
Finished products		81,447		35,290
	$	130,530	$	61,051

Revenue Recognition

Accounts receivable

Segments

A summary of the company’s reportable segments is as follows:

Total assets:

	September 30, 2016			December 31, 2015
Nutraceutical and Cosmetic Additives	$	519,646		$	412,324
Finished Cosmetic Products		695,205			101,828
Eliminations		(135,476	)		(65,681	)
Total	$	1,079,375		$	448,471

Total sales:

	Three months ended				Nine months ended
	September 30, 2016		September 30, 2015		September 30, 2016			September 30, 2015
Nutraceutical and Cosmetic Additives	$	229,741	$	279,883	$	780,961		$	845,513
Finished Cosmetic Products		1,154,688		-		3,494,743			-
Eliminations		-		-		(23,000	)		-
Total	$	1,384,429	$	279,883	$	4,252,704		$	845,513

Net (loss) income:

	Three months ended					Nine months ended
	September 30, 2016			September 30, 2015		September 30, 2016			September 30, 2015
Nutraceutical and Cosmetic Additives	$	(258,713	)	$	8,119	$	(653,757	)	$	(11,243	)
Finished Cosmetic Products		41,017			-		171,520			-
Eliminations		-			-		-			-
Total	$	(217,696	)	$	8,119	$	(482,237	)	$	(11,243	)

As of and for the nine months ended September 30, 2015, there were no assets, sales or net loss relative to the finished cosmetic products segment.

Income Taxes

The Company’s tax returns for all years since December 31, 2012, remain open to taxing authorities.

Stock-Based Compensation

Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.

Earnings (Loss) Per Share

Recent Accounting Pronouncements

Fair Value of Financial Instruments

Noncontrolling Interests

Concentration of Credit Risk

XML 18 R9.htm IDEA: XBRL DOCUMENT

Notes Payable

9 Months Ended

Sep. 30, 2016

Notes Payable [Abstract]

Notes Payable

3.	Notes Payable

XML 19 R10.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2016

Income Taxes [Abstract]

Income Taxes

4.	Income Taxes

A summary of the deferred tax asset using an approximate 34% tax rate is as follows:

Deferred Tax Asset	$	930,000
Valuation allowance		(930,000	)
Total	$	-

The net operating loss carryforwards could be subject to limitation in any given year in the event of a change in ownership as defined by IRC Section 382.

The deferred tax benefit included in the 2015 statement of operations represents the change in the deferred tax liability at each balance sheet date.

XML 20 R11.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2016

Stockholders' Equity [Abstract]

Stockholders' Equity

5.	Stockholders’ Equity

In August 2016, the Company issued 125,000 shares of common stock pursuant to sale of two promissory notes in the Offering.

In September 2016, the Company issued 62,500 shares of common stock pursuant to the sale of one promissory note in the Offering.

Service-Based Stock Options

In May 2016, the Company issued 175,000 service-based options valued at $40,829 to two consultants at exercise prices of $0.20 per share. The options are fully vested and expire in 10 years.

In July 2016, the Company issued 50,000 service-based options valued at $12,398 to a consultant with an exercise price of $0.20 per share. The options are fully vested and expire in 10 years.

Accordingly, stock based compensation for the three and nine months ended September 30, 2016 included $12,398 and $53,227, respectively, related to such options.

A Summary of the outstanding service-based options are as follows:

	Number of Options
Balance at December 31, 2015		11,025,273
Cancelled		(250,000	)
Issued		225,000

Balance at September 30, 2016		11,000,273

The significant assumptions used to determine the fair values of options issued, using a Black-Scholes option-pricing model are as follows:

Significant assumptions :
Risk-free interest rate at grant date		0.78% - 1.88	%
Expected stock price volatility		222.9% - 248.4	%
Expected dividend payout		—
Expected option life-years		2 - 3
Weighted average grant date fair value	$	0.22 - 0.26
Forfeiture rate		0	%

The following is a summary of outstanding service-based options at September 30, 2016:

Exercise Price	Number of Options		Weighted Average Remaining Contractual Life

$0.10		1,680,273		2 years
$0.20 - $0.25		8,170,000		6 years
$0.40		1,150,000		5 years
Total		11,000,273

Performance-Based Stock Options

Warrants

In September 2016, the Company issued 100,000 warrants with an exercise price of $0.50 per share, in relation to a sale of common stock. These warrants are fully vested and expire in two years.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 21 R12.htm IDEA: XBRL DOCUMENT

Royalties

9 Months Ended

Sep. 30, 2016

Royalties [Abstract]

Royalties

6.	Royalties

Included in accounts payable and accrued expenses at September 30, 2016 and December 31, 2015 was $56,579 in regards to this agreement.

XML 22 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies [Abstract]

Commitments and Contingencies

7.	Commitments and Contingencies

Leases

Employment and Consulting Agreements

Restricted Stock and Options

Legal Matters

XML 23 R14.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Sep. 30, 2016

Related Party Transactions

8.	Related Party Transactions

XML 24 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2016

Subsequent Events [Abstract]

Subsequent Events

9.	Subsequent Events

XML 25 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2016

Summary of Significant Accounting Policies [Abstract]

Unaudited Financial Statements

Unaudited Financial Statements

Basis of Presentation and Use of Estimates

Basis of Presentation and Use of Estimates

Inventory

Inventory

	September 30, 2016		December 31, 2015

Raw materials	$	49,083	$	25,761
Finished products		81,447		35,290
	$	130,530	$	61,051

Revenue Recognition

Revenue Recognition

Accounts receivable

Accounts receivable

Segments

Segments

A summary of the company’s reportable segments is as follows:

Total assets:

	September 30, 2016			December 31, 2015
Nutraceutical and Cosmetic Additives	$	519,646		$	412,324
Finished Cosmetic Products		695,205			101,828
Eliminations		(135,476	)		(65,681	)
Total	$	1,079,375		$	448,471

Total sales:

	Three months ended				Nine months ended
	September 30, 2016		September 30, 2015		September 30, 2016			September 30, 2015
Nutraceutical and Cosmetic Additives	$	229,741	$	279,883	$	780,961		$	845,513
Finished Cosmetic Products		1,154,688		-		3,494,743			-
Eliminations		-		-		(23,000	)		-
Total	$	1,384,429	$	279,883	$	4,252,704		$	845,513

Net (loss) income:

	Three months ended					Nine months ended
	September 30, 2016			September 30, 2015		September 30, 2016			September 30, 2015
Nutraceutical and Cosmetic Additives	$	(258,713	)	$	8,119	$	(653,757	)	$	(11,243	)
Finished Cosmetic Products		41,017			-		171,520			-
Eliminations		-			-		-			-
Total	$	(217,696	)	$	8,119	$	(482,237	)	$	(11,243	)

As of and for the nine months ended September 30, 2015, there were no assets, sales or net loss relative to the finished cosmetic products segment.

Income Taxes

Income Taxes

The Company’s tax returns for all years since December 31, 2012, remain open to taxing authorities.

Stock-Based Compensation

Stock-Based Compensation

Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.

Earnings (Loss) Per Share

Earnings (Loss) Per Share

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Noncontrolling Interests

Noncontrolling Interests

Concentration of Credit Risk

Concentration of Credit Risk

XML 26 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2016

Summary of Significant Accounting Policies [Abstract]

Summary of inventory

	September 30, 2016		December 31, 2015

Raw materials	$	49,083	$	25,761
Finished products		81,447		35,290
	$	130,530	$	61,051

Summary of reportable segments

Total assets:

	September 30, 2016			December 31, 2015
Nutraceutical and Cosmetic Additives	$	519,646		$	412,324
Finished Cosmetic Products		695,205			101,828
Eliminations		(135,476	)		(65,681	)
Total	$	1,079,375		$	448,471

Total sales:

	Three months ended				Nine months ended
	September 30, 2016		September 30, 2015		September 30, 2016			September 30, 2015
Nutraceutical and Cosmetic Additives	$	229,741	$	279,883	$	780,961		$	845,513
Finished Cosmetic Products		1,154,688		-		3,494,743			-
Eliminations		-		-		(23,000	)		-
Total	$	1,384,429	$	279,883	$	4,252,704		$	845,513

Net (loss) income:

	Three months ended					Nine months ended
	September 30, 2016			September 30, 2015		September 30, 2016			September 30, 2015
Nutraceutical and Cosmetic Additives	$	(258,713	)	$	8,119	$	(653,757	)	$	(11,243	)
Finished Cosmetic Products		41,017			-		171,520			-
Eliminations		-			-		-			-
Total	$	(217,696	)	$	8,119	$	(482,237	)	$	(11,243	)

XML 27 R18.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

9 Months Ended

Sep. 30, 2016

Income Taxes [Abstract]

Schedule of deferred tax asset

Deferred Tax Asset	$	930,000
Valuation allowance		(930,000	)
Total	$	-

XML 28 R19.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of significant assumptions used to determine fair values of options issued using Black-Scholes option-pricing model

Significant assumptions :
Risk-free interest rate at grant date		0.78% - 1.88	%
Expected stock price volatility		222.9% - 248.4	%
Expected dividend payout		—
Expected option life-years		2 - 3
Weighted average grant date fair value	$	0.22 - 0.26
Forfeiture rate		0	%

Summary of outstanding service-based options exercise price

Exercise Price	Number of Options		Weighted Average Remaining Contractual Life

$0.10		1,680,273		2 years
$0.20 - $0.25		8,170,000		6 years
$0.40		1,150,000		5 years
Total		11,000,273

Service-Based Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of outstanding service-based options

	Number of Options
Balance at December 31, 2015		11,025,273
Cancelled		(250,000	)
Issued		225,000

Balance at September 30, 2016		11,000,273

XML 29 R20.htm IDEA: XBRL DOCUMENT

Organization and Going Concern (Details) - USD ($)	9 Months Ended
Organization and Going Concern (Details) - USD ($)	Sep. 30, 2016	Apr. 01, 2016	Dec. 31, 2015
Organization and Going Concern (Textual)
Percentage of ownership of equity interest			33.33%
Percentage of voting controlling interest			51.00%
Accumulated deficit	$ (9,075,014)		$ (8,586,338)
Additional Paid-in Capital [Member]
Organization and Going Concern (Textual)
Reduction in noncontrolling interest	$ 91,612
Immudyne Pr Llc [Member]
Organization and Going Concern (Textual)
Percentage of ownership of equity interest		78.16667%

XML 30 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Summary of inventory
Raw materials	$ 49,083	$ 25,761
Finished products	81,447	35,290
Inventory, net	$ 130,530	$ 61,051

XML 31 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Summary of reportable segments [Line Items]
Total assets	$ 1,079,375		$ 1,079,375		$ 448,471
Total sales	1,384,429	$ 279,883	4,252,704	$ 845,513
Net (loss) income	(217,696)	8,119	(482,237)	(11,243)
Nutraceutical and cosmetic [Member]
Summary of reportable segments [Line Items]
Total assets	519,646		519,646		412,324
Total sales	229,741	279,883	780,961	845,513
Net (loss) income	(258,713)	8,119	(653,757)	(11,243)
Finished Cosmetic Products [Member]
Summary of reportable segments [Line Items]
Total assets	695,205		695,205		101,828
Total sales	1,154,688		3,494,743
Net (loss) income	(41,017)		171,520
Elimination [Member]
Summary of reportable segments [Line Items]
Total assets	(135,476)		(135,476)		$ (65,681)
Total sales			(23,000)
Net (loss) income

XML 32 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Summary of Significant Accounting Policies (Textual)
Non controlling interest rate			21.833%
Inventory reserve	$ 20,000		$ 20,000		$ 20,000
Customer discounts, returns and rebates	530,000		1,578,000
Revenue	1,384,429	$ 279,883	4,252,704	$ 845,513
Accounts receivable reserve	122,000		122,000		$ 18,000
Nutraceutical and cosmetic [Member]
Summary of Significant Accounting Policies (Textual)
Revenue	229,741	279,883	780,961	845,513
Finished Cosmetic Products [Member]
Summary of Significant Accounting Policies (Textual)
Revenue	$ 1,154,688		$ 3,494,743
Sales [Member] \| One Customer [Member] \| Nutraceutical and cosmetic [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk percentage	13.00%	81.00%	15.00%	83.00%
Sales [Member] \| Second Customer [Member] \| Nutraceutical and cosmetic [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk percentage	3.00%	13.00%	2.00%	13.00%
Accounts Receivable [Member] \| One Customer [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk percentage			0.00%		43.00%
Accounts Receivable [Member] \| One Customer [Member] \| Nutraceutical and cosmetic [Member]
Summary of Significant Accounting Policies (Textual)
Non controlling interest rate	13.00%	81.00%
Accounts Receivable [Member] \| Second Customer [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk percentage			0.00%		24.00%
Accounts Receivable [Member] \| Second Customer [Member] \| Nutraceutical and cosmetic [Member]
Summary of Significant Accounting Policies (Textual)
Non controlling interest rate	3.00%	13.00%
Option [Member] \| Warrant [Member]
Summary of Significant Accounting Policies (Textual)
Antidilutive securities excluded from computation of earnings per share	12,950,273	12,425,800	12,950,273	12,425,800

XML 33 R24.htm IDEA: XBRL DOCUMENT

Notes Payable (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
Notes Payable (Details) - USD ($)	Nov. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Notes Payable (Textual)
Borrowed from commercial lender	$ 100,000
Interest rate on notes payable	11.00%
Interest expense on notes payable		$ 2,750	$ 5,175	$ 8,250	$ 23,517
Maturity date on notes payable	Nov. 01, 2016
Interest expense		$ 9,992	14,422	15,805	33,048
Debt Instrument, Interest Rate During Period		11.00%
Debt Instrument, Term		6 months
Debt Instrument, Face Amount		$ 50,000		$ 50,000
Debt Instrument, Payment Terms				In August and September 2016, the Company sold promissory notes totaling $150,000 to three unrelated individuals. Two of the promissory notes totaling $100,000 are payable in February 2017 and one promissory note for $50,000 is payable in March 2017.
Issue of common stock, value				$ 41,875
Amortization of debt discount		5,990		5,990
Loans outstanding		150,000		150,000
Notes Payable [Member]
Notes Payable (Textual)
Interest expense on notes payable		9,992	14,422	15,805	33,048
Interest expense		1,253
Officers, Directors and Other [Member]
Notes Payable (Textual)
Interest expense on notes payable		$ 0	$ 9,247	$ 313	$ 9,531

XML 34 R25.htm IDEA: XBRL DOCUMENT

Income Taxes (Details)	Sep. 30, 2016 USD ($)
Schedule of deferred tax assets
Deferred Tax Asset	$ 930,000
Valuation allowance	(930,000)
Total

XML 35 R26.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Textual) - USD ($)	9 Months Ended	12 Months Ended
Income Taxes (Details Textual) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Income Taxes (Textual)
Net operating loss carryforwards		$ 2,730,000
Operating loss carryforwards, expiration date		Dec. 31, 2035
Percentage of tax rate	34.00%

XML 36 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - Service-Based Stock Options [Member] - shares		1 Months Ended	9 Months Ended
	Jul. 31, 2016	May 31, 2016	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning balance			11,025,273
Number of Options, Cancelled			(250,000)
Number of Options, Issued	50,000	175,000	225,000
Number of Options, Ending balance			11,000,273

XML 37 R28.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details 1)	9 Months Ended
Stockholders' Equity (Details 1)	Sep. 30, 2016 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected dividend payout
Forfeiture rate	0.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate at grant date	1.88%
Expected stock price volatility	248.40%
Expected option life-years	3 years
Weighted average grant date fair value	$ 0.26
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate at grant date	0.78%
Expected stock price volatility	222.90%
Expected option life-years	2 years
Weighted average grant date fair value	$ 0.22

XML 38 R29.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details 2) - $ / shares	9 Months Ended
Stockholders' Equity (Details 2) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Employee Stock Option [Member]
Summary of outstanding service-based options
Number of Options	11,000,273	11,025,273
$0.10 [Member]
Summary of outstanding service-based options
Exercise Price	$ 0.10
Number of Options	1,680,273
Weighted Average Remaining Contractual Life	2 years
$0.20 - $0.25 [Member]
Summary of outstanding service-based options
Number of Options	8,120,000
Weighted Average Remaining Contractual Life	6 years
$0.20 - $0.25 [Member] \| Minimum [Member]
Summary of outstanding service-based options
Exercise Price	$ 0.20
$0.20 - $0.25 [Member] \| Maximum [Member]
Summary of outstanding service-based options
Exercise Price	0.25
$0.40 [Member]
Summary of outstanding service-based options
Exercise Price	$ 0.40
Number of Options	1,150,000
Weighted Average Remaining Contractual Life	5 years

XML 39 R30.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Textual)				1 Months Ended	3 Months Ended		9 Months Ended
Stockholders' Equity (Details Textual)	Sep. 01, 2016 USD ($) $ / shares shares	Jul. 31, 2016 USD ($) Consultants $ / shares shares	Apr. 01, 2016 USD ($) shares	May 31, 2016 USD ($) Consultants $ / shares shares	Sep. 30, 2016 USD ($) $ / shares shares	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) $ / shares shares	Sep. 30, 2015 USD ($)	Aug. 31, 2016 shares	Dec. 31, 2015 USD ($) shares
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common stock issued for services as per agreement							$ 306,667
Recognized expense					$ 76,667		306,667
Intrinsic value of options exercisable					750,294		750,294
Intrinsic value of options outstanding					750,294		$ 750,294
Stock options, Expiration period	2 years
Stock options, Expiration date							Dec. 31, 2017
Stock based compensation							$ 493,218	$ 14,500
Unearned share based compensation					$ 133,324		$ 133,324
Weighted average exercise price of warrants outstanding \| $ / shares	$ 0.50				$ 0.50		$ 0.50
Warrants issued \| shares	100,000				100,000		100,000
Issuance of warrants for services							$ 581,093
Common stock, shares issued \| shares	200,000				34,697,875		34,697,875			32,010,375
Common stock issued, value	$ 46,000				$ 346,978		$ 346,978			$ 320,103
Outstanding shares purchased \| shares					19,363		19,363
Purchase of common stock description					Company common stock through an exchange for a price per share of $0.23 to $0.26.
Treasury Stock, Value					$ 4,720		$ 4,720
IPO [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common stock, shares issued \| shares					62,500		62,500		125,000
Two consultants [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common stock issued for services as per agreement, shares \| shares			2,300,000
Common stock issued for services as per agreement			$ 690,000
Performance Based Stock Options [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Recognized expense					$ 165,241	$ 10,500	$ 513,804	$ 14,500
Number of stock options issued \| shares							4,400,000
Stock based compensation					55,591		$ 133,324
Unearned share based compensation					35,711		35,711
Fair value of performance-based stock options							$ 169,035
Performance Based Stock Options [Member] \| Minimum [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock options, Expiration date							Dec. 31, 2021
Weighted average exercise price stock option issued \| $ / shares							$ 0.40
Annual sales revenue target							$ 5,000,000
Performance Based Stock Options [Member] \| Maximum [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock options, Expiration date							Dec. 31, 2026
Weighted average exercise price stock option issued \| $ / shares							$ 0.80
Annual sales revenue target							$ 10,000,000
Service-Based Stock Options [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Number of stock options issued \| shares		50,000		175,000			225,000
Stock option issued, value		$ 12,398		$ 40,829
Stock options, Expiration period		10 years		10 years
Weighted average exercise price stock option issued \| $ / shares		$ 0.20		$ 0.20
Stock based compensation					$ 12,398		$ 53,227
Number of consultant \| Consultants		1		2
Warrant [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Warrants outstanding \| shares					1,950,000		1,950,000			1,750,000
Warrant exercisable \| shares					1,950,000		1,950,000			1,750,000
Weighted average exercise price of warrants outstanding \| $ / shares					$ 0.19		$ 0.19
Warrant expiration date, description							Warrants expire during November 2016 and September 2019.
Warrants issued \| shares					100,000		100,000
Issuance of warrants for services							$ 20,585
Warrant [Member] \| Minimum [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Weighted average exercise price of warrants outstanding \| $ / shares					$ 0.20		$ 0.20
Warrant [Member] \| Maximum [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Weighted average exercise price of warrants outstanding \| $ / shares					$ 0.50		$ 0.50

XML 40 R31.htm IDEA: XBRL DOCUMENT

Royalties (Details) - USD ($)	9 Months Ended		12 Months Ended
Royalties (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Royalties (Textual)
Royalty based upon sales amount	$ 227,175
Percentage of royalty based upon sales	8.00%
Royalty expense	$ 0	$ 20,157
Accounts payable and accrued expenses	$ 56,579		$ 56,579
President [Member]
Royalties (Textual)
Interest in royalty			60.00%
Royalties payable			$ 84,868
Common stock shares issued			499,225
Stock price per share			$ 0.17

XML 41 R32.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - USD ($)		3 Months Ended		9 Months Ended
Commitments and Contingencies (Details) - USD ($)	Apr. 01, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Commitments and Contingencies (Textual)
Lease expiration date				May 31, 2016
Monthly lease rental payments				$ 9,000
Operating leases, rent expense		$ 27,706	$ 15,286	71,606	$ 50,350
Salaries, wages and officers compensation				$ 145,000
Stock option exercise price lower range limit				$ 0.40
Stock option exercise price upper range limit				$ 0.80
Stock issued during period performance based options to purchase common stock		4,400,000		4,400,000
Percentage of bonus compensation for pretax income				15.00%
Common stock issued for services as per agreement				$ 306,667
Stock options, Expiration date				Dec. 31, 2017
share price		$ 0.30		$ 0.30
Two consultants [Member]
Commitments and Contingencies (Textual)
Common stock issued for services as per agreement	$ 690,000
Restricted Stock and Options [Member]
Commitments and Contingencies (Textual)
Consultant agreements Description				The Company has entered into two agreements on April 1, 2016 with two consultants of Immudyne PR for business development, marketing and sales related services (the “Consultant Agreements”). Upon signing, each consultant was issued 1,000,000 restricted shares of Immudyne, Inc. common stock. In addition, each consultant shall receive an additional 150,000 restricted shares of Immudyne, Inc. common stock for each $500,000 distributed by Immudyne PR to the Company. For each consultant the amount of shares to be issued by the Company to the consultants shall be capped at 1,500,000 restricted shares when Immudyne PR has transferred $5,000,000 to the Company, for a combined capped total of 3,000,000 restricted shares. For the three and nine months ended September 30, 2016, 2,300,000 restricted shares of common stock have been issued related to these agreements. In addition, the Consulting Agreements provided that each consultant shall receive a bonus of an additional 750,000 restricted shares of Immudyne Inc. common stock, plus an option to buy 1,000,000 shares of Immudyne, Inc. common stock at $0.20/share (including a cashless exercise feature) when Immudyne PR has transferred to the Company at each of the following three (3) thresholds: $1,250,000, $2,000,000 and $3,000,000 for a total of 2,250,000 of restricted shares of Immudyne, Inc. common stock and options to purchase up to 3,000,000 shares of Immudyne, Inc. common stock at $0.20/share. As of September 30, 2016, no bonus shares have been issued and no options have been granted under this agreement.
Restricted shares issued	1,000,000			2,300,000
Option to buy shares				1,000,000
Additional bonus shares				750,000

XML 42 R33.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - USD ($)	3 Months Ended	9 Months Ended
Related Party Transactions (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2016
Related Party Transactions (Textual)
Compensation for legal services provided by director	$ 6,000	$ 15,000
Reimbursement of home office expenditures received by director	$ 6,000	$ 20,000

XML 43 R34.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - USD ($)		9 Months Ended
Subsequent Events (Details) - USD ($)	Oct. 31, 2016	Sep. 30, 2016	Nov. 30, 2016
Subsequent Events (Textual)
Issuance of company stock, value		$ 46,000
Principal payment		$ 50,000
Subsequent Event [Member]
Subsequent Events (Textual)
Note repaid			$ 100,000
Notes issued	$ 50,000
Common stock issued	62,500
Issuance of company stock, value	$ 7,382
Issuance of Company stock, shares	27,637
Principal payment	$ 18,800

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 119 188 1 false 31 0 false 5 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.immudyne.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - Consolidated Balance Sheets Sheet http://www.immudyne.com/role/Consolidatedbalancesheets Consolidated Balance Sheets Statements 2 false false R3.htm 003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.immudyne.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://www.immudyne.com/role/ConsolidatedStatementsOfOperationsUnaudited Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 005 - Statement - Consolidated Statement of Stockholders' Equity (Unaudited) Sheet http://www.immudyne.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited Consolidated Statement of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlowsUnaudited Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 007 - Disclosure - Organization and Going Concern Sheet http://www.immudyne.com/role/OrganizationAndGoingConcern Organization and Going Concern Notes 7 false false R8.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 009 - Disclosure - Notes Payable Notes http://www.immudyne.com/role/NotesPayable Notes Payable Notes 9 false false R10.htm 010 - Disclosure - Income Taxes Sheet http://www.immudyne.com/role/IncomeTaxes Income Taxes Notes 10 false false R11.htm 011 - Disclosure - Stockholders' Equity Sheet http://www.immudyne.com/role/StockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 012 - Disclosure - Royalties Sheet http://www.immudyne.com/role/Royalties Royalties Notes 12 false false R13.htm 013 - Disclosure - Commitments and Contingencies Sheet http://www.immudyne.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 014 - Disclosure - Related Party Transactions Sheet http://www.immudyne.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 015 - Disclosure - Subsequent Events Sheet http://www.immudyne.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 016 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 017 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 018 - Disclosure - Income Taxes (Tables) Sheet http://www.immudyne.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.immudyne.com/role/IncomeTaxes 18 false false R19.htm 019 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.immudyne.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.immudyne.com/role/StockholdersEquity 19 false false R20.htm 020 - Disclosure - Organization and Going Concern (Details) Sheet http://www.immudyne.com/role/OrganizationAndGoingConcernDetails Organization and Going Concern (Details) Details http://www.immudyne.com/role/OrganizationAndGoingConcern 20 false false R21.htm 021 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 022 - Disclosure - Summary of Significant Accounting Policies (Details 1) Sheet http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails1 Summary of Significant Accounting Policies (Details 1) Details http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables 22 false false R23.htm 023 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.immudyne.com/role/Summaryofsignificantaccountingpoliciesdetailstextual Summary of Significant Accounting Policies (Details Textual) Details http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 024 - Disclosure - Notes Payable (Details) Notes http://www.immudyne.com/role/NotesPayableDetails Notes Payable (Details) Details http://www.immudyne.com/role/NotesPayable 24 false false R25.htm 025 - Disclosure - Income Taxes (Details) Sheet http://www.immudyne.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.immudyne.com/role/IncomeTaxesTables 25 false false R26.htm 026 - Disclosure - Income Taxes (Details Textual) Sheet http://www.immudyne.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) Details http://www.immudyne.com/role/IncomeTaxesTables 26 false false R27.htm 027 - Disclosure - Stockholders' Equity (Details) Sheet http://www.immudyne.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.immudyne.com/role/StockholdersEquityTables 27 false false R28.htm 028 - Disclosure - Stockholders' Equity (Details 1) Sheet http://www.immudyne.com/role/StockholdersEquityDetails1 Stockholders' Equity (Details 1) Details http://www.immudyne.com/role/StockholdersEquityTables 28 false false R29.htm 029 - Disclosure - Stockholders' Equity (Details 2) Sheet http://www.immudyne.com/role/StockholdersEquityDetails2 Stockholders' Equity (Details 2) Details http://www.immudyne.com/role/StockholdersEquityTables 29 false false R30.htm 030 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.immudyne.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://www.immudyne.com/role/StockholdersEquityTables 30 false false R31.htm 031 - Disclosure - Royalties (Details) Sheet http://www.immudyne.com/role/RoyaltiesDetails Royalties (Details) Details http://www.immudyne.com/role/Royalties 31 false false R32.htm 032 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.immudyne.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.immudyne.com/role/CommitmentsAndContingencies 32 false false R33.htm 033 - Disclosure - Related Party Transactions (Details) Sheet http://www.immudyne.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.immudyne.com/role/RelatedPartyTransactions 33 false false R34.htm 034 - Disclosure - Subsequent Events (Details) Sheet http://www.immudyne.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.immudyne.com/role/SubsequentEvents 34 false false All Reports Book All Reports immd-20160930.xml immd-20160930.xsd immd-20160930_cal.xml immd-20160930_def.xml immd-20160930_lab.xml immd-20160930_pre.xml true true ZIP 50 0001213900-16-018505-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-16-018505-xbrl.zip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end